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SUMMARY
To elucidate the deregulated functional modules that
drive clear cell renal cell carcinoma (ccRCC), we per-
formed comprehensive genomic, epigenomic, tran-
scriptomic, proteomic, and phosphoproteomic char-
acterization of treatment-naive ccRCC and paired
normal adjacent tissue samples. Genomic analyses
identified a distinct molecular subgroup associated
with genomic instability. Integration of proteoge-
nomic measurements uniquely identified protein
dysregulation of cellular mechanisms impacted by
genomic alterations, including oxidative phosphory-
lation-related metabolism, protein translation pro-
cesses, and phospho-signaling modules. To assess
the degree of immune infiltration in individual tu-
mors, we identified microenvironment cell signatures
that delineated four immune-based ccRCC subtypes
characterized by distinct cellular pathways. This
study reports a large-scale proteogenomic analysis
of ccRCC to discern the functional impact of genomic
alterations and provides evidence for rational treat-
ment selection stemming from ccRCC pathobiology.
INTRODUCTION
Renal cell carcinoma (RCC) is among the top tenmost commonly
diagnosed cancers worldwide (Siegel et al., 2018). Clear cell
renal cell carcinoma (ccRCC) is the predominant histology of
renal cell carcinoma, representing 75% of all cases and the ma-
jority of cancer-associated deaths (Hsieh et al., 2017). To under-
stand the underlying molecular alterations that drive ccRCC
oncogenesis, The Cancer Genome Atlas (TCGA) has performed
extensive genomic, epigenomic, and transcriptomic profiling,
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identifying discriminating features of ccRCC that include loss of
various tumor suppressor genes (Creighton et al., 2013; Ricketts
et al., 2018). Aberrant dysregulation of the VHL gene is a nearly
universal founding event. Subsequent genomic alterations
involving PBRM1, SETD2, KDM5C, or BAP1 are required for dis-
ease progression and are associated with aggressive pheno-
types (Hakimi et al., 2013; Kapur et al., 2013). These studies
have highlighted the value of molecular characterization, in addi-
tion to histological assessment, to stratify ccRCC patients, while
identifying genomic features unique to ccRCC tumorigenesis
(Chen et al., 2016a).
Historically, ccRCC has been considered resistant to conven-
tional chemotherapy and radiotherapy, with surgical resection as
the primary treatment for localized tumors (Blanco et al., 2011;
Diamond et al., 2015). Despite several Food and Drug Adminis-
tration (FDA)-approved agents that target cellular pathways
prioritized by genomic analyses, response of ccRCC patients
to these treatments has been limited (Hsieh et al., 2018a). These
results illustrate the complexity of tumorigenesis processes and
suggest that genomic, epigenomic, and transcriptomic profiling
alone may be insufficient to interrogate this cancer type fully for
identifying effective curative treatments. In this study, the Clinical
Proteomics Tumor Analysis Consortium (CPTAC) has performed
a comprehensive proteogenomic characterization of treatment-
naive tumors and paired normal adjacent tissues (NATs) to
elucidate the impact of genomic alterations driving phenotypic
perturbations and to delineate themechanisms of ccRCC patho-
biology for prospective exploration of personalized, precision-
based clinical care.
RESULTS
Proteogenomic Analyses of Tumor and NAT Specimens
In this study, 110 treatment-naive RCC and 84 paired-matched
NAT samples were analyzed using a proteogenomic approach
wherein each tissue was homogenized via cryopulverization
and aliquoted to facilitate genomic, transcriptomic, and proteo-
mic analyses on the same tissue sample (STARMethods). Patient
characteristics, including age, gender, race, and tumor grade and
stage, were recorded for all cases and summarized in Table S1.
Proteomics and phosphoproteomics analyses identified a total
of 11,355 proteins and 42,889 phosphopeptides, respectively,
of which 7,150 proteins and 20,976 phosphopeptides were quan-
tified across all samples (STAR Methods). To enable multi-omics
data integration and proteogenomic analysis, whole genome
sequencing (WGS), whole exome sequencing (WES), and total
RNA sequencing (RNA-seq) were performed for all 110 tumor
samples, while 107 tumor samples had quality DNA methylation
profiling data (Figure S1A; Table S1). NAT samples with mRNA
of sufficient quality were subjected to total RNA-seq (n = 75).
One NAT sample that displayed discordant proteogenomic pro-
files was found to contain significant histological evidence of
tumor tissue and was excluded from downstream analyses (Fig-
ure S1A; Table S1). In addition to the initial pathological diagnosis,
we leveraged the molecular information available for RCCs by
TCGA and others to verify further the histological classification
of tumor samples (STAR Methods; Creighton et al., 2013; Davis
et al., 2014; Mehra et al., 2016, 2018; Linehan et al., 2016). Sam-
ple-wise assessment of genomic profiles identified seven tumors
with molecular aberrations atypical for ccRCC, such as lacking
the characteristic bi-allelic loss of tumor suppressor genes on
3p (Figures S1B–S1D; Table S2). While these seven non-ccRCC
samples and their corresponding NATs (n = 3) were excluded
frommost subsequent analyses, the non-ccRCC samples served
as useful controls to highlight ccRCC-specific features. Overall,
data from 103 ccRCC and 80 NAT tissue samples (with RNA-
seq profiles available for 72 samples) were examined for compre-
hensive proteogenomic characterization (Table S1).
Genomic Landscape of the CPTAC ccRCC Cohort
Our study represents a large WGS analysis of ccRCC, revealing
arm-level loss of chromosome 3p as the most frequent event
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(93%), followed by chromosome 5q gain (54%), chromosome
14q loss (42%), chromosome 7 gain (34%), and chromosome
9 loss (21%) (Figure 1A; Table S2). Strikingly, we observed
fourteen tumors in our cohort displayed extensive CNVs across
all chromosomes, indicating a high degree of genomic insta-
bility. A molecular subset with these characteristics was not
identified in the initial TCGA ccRCC study, possibly due to
the limited number of tumors examined via WGS (Creighton
et al., 2013). Moreover, a recent pan-cancer analysis of three
common RCC subtypes and studies investigating ccRCC
tumor ploidy via an intra-tumor heterogeneity approach showed
a significant association between high genome aneuploidy
and poor prognosis (Chen et al., 2016a; Turajlic et al.,
2018a, 2018b), which is consistent with the enrichment of ge-
nomically instable high grade tumors identified in our study
(Figure 1A).
Figure 1. Genomic Alterations and their
Associations with mRNA, Protein, and
Phosphoprotein Abundances
(A) Profiling of absolute copy number estimates
observed in the CPTAC cohort. Genomically
defined non-ccRCC tumors are above ccRCC tu-
mors; translocation event, grade, CpG island
methylator phenotype (CIMP) status, genome
instability, and CNV loss/gain are indicated by
color coding. ccRCC tumors with evidence of 3p
loss of heterozygosity (LOH) are indicated by three
asterisks (***).
(B) Circos plots of translocation events involving
chromosomes 3 and either chromosomes 5 (red),
2 (blue), 8 (purple) or all other chromosomes (gray),
including chromosomal inversion within chromo-
some 3 (green). Percentage of involved tumors
with re-arrangement for each chromosome is an-
notated below each plot.
(C) Heatmap of multi-omic data for the five key
tumor suppressor genes (VHL, PBRM1, BAP1,
SETD2, and KDM5C) (n = 103). Tumor samples
were ordered by 3p CNV alteration (loss to
neutral). Non-ccRCC tumors are separated (right).
CNV event, Z score, CNV loss/gain, translocation
status, CpG island methylator phenotype (CIMP)
status, genome instability, grade, and gender are
indicated by color coding (bottom).
See also Figure S1 and Tables S1 and S2.
A previous report identified chromo-
some translocation as a mechanism of
concurrent 3p loss and 5q gain in ccRCC
(Mitchell et al., 2018). Utilizing the WGS
data in our study, we investigated the fre-
quency and types of chromosomal rear-
rangements present in our cohort. We
observed that 61% of ccRCC cases
displayed one or more translocation
events, predominantly involving the chro-
mosome 3p locus and chromosomes 5
(20%), 2 (11%), and 8 (7%) among others
(Figure 1B; Table S2). The novel chro-
mosome t(3:2) rearrangement, largely
observed in cases with concurrent 3p loss and 2q gain, was
the second most common translocation event and was nearly
mutually exclusive with t(3:5) (Figure 1B). We also detected chro-
mosomal inversion within chromosome 3 (n = 2) that resulted in
concurrent 3q gain and 3p loss (Figure 1B). A previous study
suggested chromothripsis as a likely mechanism of concurrent
3p loss and 5q gain in ccRCC (Mitchell et al., 2018); we noted
a similar genomic feature of oscillating copy number patterns
near the breakpoint (data not shown). In addition, 3p loss of
heterozygosity (LOH) was observed in six tumors (Table S2). In
total, 102 of 103 ccRCC tumors in the CPTAC cohort showed
evidence of 3p dysregulation.
The profile of somatic mutations in the CPTAC ccRCC cohort
was reflective of that previously described by TCGA (Creighton
et al., 2013). Dysregulation of VHL was the most frequent alter-
ation and was observed in 85% of tumors. PBRM1, BAP1,
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KDM5C, and SETD2 followed with mutation rates of 43%, 17%,
18%, and 16%, respectively (Figure 1C). We further examined
the impact of mutation and methylation of these genes on their
respective levels of mRNA and protein. Overall, inactivating
genomic events resulted in reduced expression of mRNA and
protein (Figure 1C), indicating loss-of-function and supporting
the classification of these genes as ccRCC tumor suppressors
(Frew and Moch, 2015; Liao et al., 2015). Unique to SETD2
was the relationship of gene inactivation due to t(3:2), with a
higher frequency of mutations and reduced protein expression
relative to other translocation events involving chromosome 3p
(Figures S1E and S1F). Investigation into the rate of mutation
co-occurrence revealed that VHL mutations were associated
with the presence of other mutations (PBRM1, BAP1, SETD2,
and KDM5C), while PBRM1mutations were associated with mu-
tation of SETD2 and KDM5C but not BAP1 (Figure S1G). These
results support a model of branched evolution in ccRCC and
the largely mutual exclusivity of somatic mutations involving
PBRM1 and BAP1 (Gerlinger et al., 2014; Turajlic et al., 2018a).
Increased methylation of promoter CpG islands contributes to
an oncogenic phenotype (Baylin and Jones, 2011). Querying
DNA methylation status of CpG positions with a previously re-
ported CpG island methylator phenotype (CIMP) marker panel
specific for ccRCC (Arai et al., 2012), we classified tumors in
our cohort into CIMP (negative) and CIMP+ (positive) categories
(Figure S1H). We identified 36 tumors (34%) with CIMP+ status,
whichwas associated with higher grade (p < 9.0 e05) and stage
(p < 0.001), and higher frequency of genomic instability (p <
0.004) (Figure 1A; Table S2).
Integrated Proteogenomic Analyses of Genomic
Alterations
Genomic alterations can impact mRNA and protein abundance
at the same locus (cis-effects), as well as other loci (trans-
effects). Through integration of mRNA, protein, and phospho-
peptide levels, we identified genomic alterations preserved
through transcriptional, translational, and post-translational
levels (cis-effect cascades), prioritizing gene targets associated
with tumor grade and differential abundance between tumors
and NATs (Figures 2A, S2A, and S2B; Table S3). Examples of
identified CNV cis-cascades included SQSTM1 (5q35.3),
OSBPL3 (7p15.3), and GOLPH3 (5q13.3), previously associated
with PI3K-mTOR signaling (Creighton et al., 2013; Lehto andOlk-
konen, 2003; Scott et al., 2009). We also identified a cis-cascade
involving the multifunctional transcription factor YY1 (14q32.2),
which is a stabilizer of HIF-1a, co-repressor of HIF-2a activity,
and inhibitor of MYC function (Austen et al., 1998; Petrella and
Brinckerhoff, 2009; Wu et al., 2013). The latter observation sug-
gests a mechanism whereby YY1 loss links the HIF-2a signaling
with MYC expression in ccRCC (Gordan et al., 2008). Investiga-
tion into methylation events proximal to VHL identified three
genes, VGLL4 (3p25.2), PLCL2 (3p24.3), and IQSEC1 (3p25.2)
with associated cis-regulated effects (Figure S2C). Methylation
of PLCL2 and IQSEC1 has been noted previously (Dmitriev
et al., 2014); however, methylation of VGLL4 has not been
reported. Its functional role inhibiting YAP-induced cell prolifera-
tion (Zhang et al., 2014b) may represent another tumor suppres-
sor gene in ccRCC. Interestingly, unique to IQSEC1, we found
that gene methylation was associated with reduced protein
and phosphorylation levels, but not mRNA. This distinctive
feature of methylation affecting protein but not mRNA expres-
sion was also observed in several other genes, including
BCL9L (11q23.3) and AHDC1 (1p35.3) (Figure S2C; Table S3),
and may indicate a post-translational regulatory mechanism.
Next, we focused on identifying cellular processes correlated
with cis- and trans-effects driven by major CNV or mutation
events in ccRCC and identified multiple pathways that were
disparate or commonly dysregulated among distinct genomic al-
terations (Figures 2B and S2D; Table S3). Loss of chromosome
3p was associated with upregulation of hypoxic signaling, cell-
cycle regulation and glycolysis, downregulation of oxidative
phosphorylation (OXPHOS), fatty acid metabolism, and the
TCA cycle. Increased expression of HIF-1a and HIF-2a is a
mechanism for upregulating hypoxic signaling upon VHL loss
(Guo et al., 2011; Krieg et al., 2000). In cancer cells, HIF1
signaling alters mitochondrial activity and drives a metabolic
shift from OXPHOS to glycolysis (Papandreou et al., 2006).
Investigation of trans-effects involving chromosome 3p genes
revealed that VHL mutations resulted in dysregulation of similar
pathways as 3p loss including downregulation of metabolic
pathways and upregulation of G1/S cell-cycle transition and
interferon-a response. PBRM1 mutations drove downregulation
of OXPHOS and upregulation of G2/M cell-cycle transition,
mitogen-activated protein kinase (MAPK) signaling, and focal
adhesion pathways.BAP1mutations were associated with upre-
gulation of protein translation pathways and interferon-g
signaling, with the latter feature also associated with SETD2mu-
tations (Figure S2D; Table S3). KD5MC mutations shared a
similar trans-effect profile as 3p locus/VHL loss, including down-
regulation of select metabolic pathways and increased cell-cycle
regulation. 5q gain resulted in increased mTORC1 and MYC
signaling, while gain of 7p drove increased protein translation
and epithelial mesenchymal transition (EMT) (Figure 2B). 9p
loss, which includes the tumor suppressor CDKN2A, was asso-
ciated with upregulation of translation initiation, mTOR and MYC
signaling, consistent with loss of CDKN2A and MYC activation
previously reported in ccRCC progression (Bailey et al., 2017).
Loss of 14q, involving the potential tumor suppressors NDRG2
(14q11.2) and HIF1A (14q23.2) (Lusis et al., 2005; Shen et al.,
2011), displayed decreasedWNT signaling expression and upre-
gulation of MYC signaling, N-linked glycosylation, and inter-
feron-g response. We detected a high percentage of CIMP+
tumors with 14q loss (75%) (Figure 1C). CIMP+ tumors shared
a similar trans-effect profile, including increased MYC signaling
and protein translation, with a unique signature associated with
increased OXPHOS and decreased focal adhesion (Figure 2B;
Table S3).
Correlation of Transcriptome and Proteome Expression
To understand the regulatory relationship between transcrip-
tomic and proteomic processes, we calculated gene-wise
(inter-sample) and sample-wise (intra-sample) correlation of
7,027 mRNA-protein pairs for the 103 ccRCC tumors and 72
NATs. NATs displayed a median gene-wise correlation value of
0.34, while tumors displayed a higher median value of 0.43,
which is similar to previous studies investigating colorectal and
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Figure 2. Impact of Copy Number Variation (CNV) on Protein Abundance
(A) DNA variations (CNV baf, B-allele frequencies; CNV lr, adjusted log coverage ratios; DNA methylation) with cascading cis-association (associations with all
types ofmRNA, global protein, and phosphopeptide abundances), overlappedwith phosphopeptides significantly differentiated by clinical features (tumor versus
NAT and tumor grade). Genes in bold are associated with CNV events involving chromosome 5 or 7 gain and 14 loss.
(B) The cis and trans associations of chromosome arms (3p, 5q, 7p, 9p, and 14q) and CpG island methylator phenotype (CIMP). Significant (adjusted p < 0.1)
positive (red) and negative (blue) associations for individual chromosomes (left), summed associations (middle), and corresponding enriched upregulated (red)
and downregulated (blue) pathways (adjusted p < 0.05) are annotated (right).
See also Figure S2 and Table S3.
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high grade serous ovarian cancers (Figure 3A; Table S4; Zhang
et al., 2014a, 2016). For ccRCC tumors and NATs, 74% and
52% of mRNA-protein pairs had significant positive Spearman
correlations, respectively (Figure 3A; Benjamini-Hochberg
adjusted p < 0.01), with OXPHOS, spliceosome, and ribosome
pathways poorly correlated in tumors. In NATs, the house-
keeping activities of the spliceosome and ribosome displayed
a distinct correlation pattern, representing a differentially regu-
lated axis to maintain cellular homeostasis (Komili and Sil-
ver, 2008).
Examination of sample-wise mRNA-protein correlation indi-
cated a lowermedian sample-wise correlation for tumor samples
(0.44) than for NAT samples (0.52), which had lower variance
(Figures 3B and S3A; Benjamini-Hochberg adjusted p < 0.001).
Adjusting for tumor purity (STAR Methods), we detected a trend
of higher sample-wise correlation in tumors associated with clin-
ical features such as higher grade (p = 0.006), chromosome 14
loss (p = 0.0006), and BAP1 mutations (p = 0.00004) (Figure 3B;
Table S4). Linking high sample correlation to increased protein
translation, we identified a concordant increase of ribosome
and translation factor protein expression (Figure 3C). Delineating
a mechanism of increased ribosome biogenesis via Pol I tran-
scription regulation (Pelletier et al., 2018), we detected a corre-
sponding increase of protein expression for MYC-targets and
mTORC1 signaling genes (p < 0.05), increased mRNA levels of
the Pol I transcription activator, ECT2 (p < 0.05), and decreased
mRNA levels for the Pol I transcription inhibitor, FGF13, in tumors
with high sample-wise correlation compared to those with low
sample-wise correlation (Figure 3C). In contrast, corresponding
NATs did not display differences between the tumor-based clas-
sifications of high/low sample-wise correlation or express differ-
ential levels of ribosome and translation-related proteins (Figures
3C, S3B, and S3C). Interestingly, there was a concerted shift of
discordant ribosome protein-mRNA levels in tumors (Figure 3C).
However, the dysregulated mechanisms that contribute to the
uncoupling of ribosomal mRNA and protein expression in tumors
are less clear, suggesting the importance of protein evidence
when evaluating ribosome biogenesis as a therapeutic target
for intervention in ccRCC (Devlin et al., 2016).
Proteogenomic Alterations of ccRCCCompared toNATs
Visualization of the abundance of identified proteins by principal
component analysis (PCA) and hierarchical clustering showed
clear discrimination between ccRCC (n = 103) and NAT samples
(n = 80) (Figures 4A and S4A). In total, 820 proteins showed sig-
nificant differential expression in a group comparison of tissue
samples (log2 fold-change >1; Benjamini-Hochberg adjusted
p < 0.05), with 565 proteins downregulated and 255 upregulated
in ccRCC tumors relative to NATs (Figure S4B; Table S5). Enrich-
ment analysis revealed immune response, EMT, and multiple
signaling pathways (hypoxia, glycolysis, and mTOR) to be upre-
gulated in tumors, and TCA cycle, fatty acid metabolism, and
OXPHOS to be downregulated (adjusted p < 0.05; Figure 4B).
Select cellular pathways weremaintained even when accounting
for tissue heterogeneity in both tumors and NAT samples (Table
S5). ccRCC tumors are characterized by particular genomic
alterations that have resulted in their classification as ametabolic
disease (Wettersten et al., 2017), which prompted us to identify
and annotate differentially abundant mRNA transcripts and
proteins involved in cellular metabolism (Figure 4C; Table S4).
Proteins in the glycolysis pathway and their cognate mRNAs
were upregulated in this analysis, whereas proteins associated
with OXPHOS were downregulated. A non-linear correlation
has been previously observed between metabolic mRNA levels
and corresponding glycolytic and OXPHOS metabolites in
ccRCC (Hakimi et al., 2016). Analyzing the differential abun-
dances of mRNA and protein levels between tumors and NAT re-
vealed a prominent uncoupling of OXPHOS mRNA and protein
expression that was disparate from other cellular pathways (Fig-
ures 4C–4E and S4C), which reflects the regulation of select
OXPHOS components at the translational level (Richman et al.,
2016). Together, these results show that the functional conse-
quences of the Warburg effect are not fully captured at the
transcriptional level, which could impact the clinical use of tran-
scription-based metabolic signatures for prognosis of ccRCC
(Creighton et al., 2013).
Phosphoproteomic Analysis of Kinase and Substrate
Regulatory Pathways
Phosphorylation impacts multiple cellular processes, with site
occupancy tightly regulated by the activity of kinases and phos-
phatases on their respective substrates (Ubersax and Ferrell,
2007). We analyzed differential phosphopeptide abundance
between 80 tumor/NAT paired tissues to stratify phospho-sub-
strates corresponding to different kinases and their inhibitors,
and identified CDK1 and MAPK1 (ERK2) as two highly ranked
phospho-substrate events in most tumors. (Figure 5A; Table
S6). A more comprehensive investigation of the cell-cycle regu-
latory network using phosphosite abundance revealed that
phosphorylated substrates associated with S-phase entry/
progression (CDK7-MCM2) and the G2/M checkpoint (WEE1-
CDK1) were elevated across the majority of tumors (Figure 5A).
The G2/M checkpoint is the final safeguard of genomic fidelity
prior to mitosis; our data support a mechanism of G2-stalling
that preventsmitotic arrest-induced apoptosis in tumors (Bucher
and Britten, 2008), evidenced by elevated levels of the inhibitory
CDK1-Y15 phosphorylation, especially in more aggressive tu-
mors (p < 0.05) (Figure S5B). Comprehensive examination of
the signaling network involving MAPK1 revealed increased pro-
tein and phospho-peptide expression of the upstream receptor
tyrosine kinase epidermal growth factor receptor (EGFR) in
almost all tumors, while vascular endothelial growth factor
(VEGF) receptors such as FLT and KDR were more selectively
expressed and phosphorylated in tumors (Figures 5A and
S5A). Additionally, we inferred activated signaling from elevated
substrate phosphosite occupancy. This analysis indicated that
activation of the EGFR/VEGF downstream signaling pathways
MAPK/ERK and AKT-mTOR converged on the downstream sub-
strate EIF4EBP1 (Figures 5A and 5B), an important regulator of
protein translation (She et al., 2010). This observation of cell
signaling redundancy may explain the limited clinical response
of ccRCC patients to mTOR-targeted therapies such as everoli-
mus and temsirolimus (Kwiatkowski et al., 2016), suggesting that
combinational therapy targeting both mTOR and MAPK/ERK
pathways may be a more effective approach. In addition, activa-
tion of mTOR signaling via the phosphorylation of the mTORC1
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Figure 3. Correlations between Transcriptomic and Proteomic Abundance
(A) Gene-wise correlations of mRNA and protein expression in tumors (left) and NATs (right). Annotated cellular pathways and corresponding Spearman gene-
wise correlation (bottom).
(B) Sample-wise correlation of tumors ranked from high to low with corresponding NAT sample-wise correlation (top). Tumors were evenly distributed into three
groups: high (blue), middle (gray), and low (gold). BAP1 mutation, chromosome 14 loss status, and tumor grade are annotated (bottom).
(C) Boxplots of ribosome and translation factor gene expression and Pol I-associated regulation in tumor samples (left) and corresponding NATs (right) (*p < 0.05).
Figure S3 and Tables S1 and S4.
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Figure 4. Differential Expression of Transcriptomic and Proteomic Profiles between ccRCC Tumors and NAT Protein Expression
(A) PCA visualization of protein expression in ccRCC tumors and NATs.
(B) Analysis of significantly differentially regulated pathways (adjusted p < 0.05) between ccRCC tumors and NATs.
(C) Schema of metabolic pathways (glycolysis and electron transport chain [OXPHOS]) with select differential gene expression of mRNA and protein levels
between ccRCC tumors and NATs.
(D) Scatterplots depicting expression of mRNA (x axis) and protein (y axis). Linear regression of all mRNA-protein pairs (gray dotted line) and OXPHOS mRNA-
gene pairs (red dotted line) are shown. Metabolism-related genes are indicated.
(E) Boxplot of representative OXPHOS genes from complex I (NDUFV2), IV (COX6C), and V (ATP6V1F) displaying discordant mRNA-protein expression (n.s., not
significant, *adjusted p < 0.05).
See also Figure S4 and Tables S1, S4, and S5.
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subunit, AKT1S1 (Vander Haar et al., 2007), was observed in
phosphoproteomic analysis but was not captured at the tran-
scriptomic level (Figure S5C), highlighting the added value of
phosphoproteomics in integrative analyses. Independent of
EGFR-mediated MAPK/AKT signaling, PKM phosphorylation
was highly ranked in approximately half of our ccRCC tumor
cohort and associated with lower tumor grade (p < 0.05) (Figures
5A and S5B), reflecting a secondary, EGFR-mediated mecha-
nism of glycolytic reprogramming in a subset of ccRCC tumors
(Lim et al., 2016).
Leveraging differential phosphopeptide abundance across
all tumor samples, we identified several phosphopeptide co-
expression networks including two modules (cell cycle and
angiogenesis) that were independent of global proteomic and
transcriptomic profiles (Figures 5C, 5D, and S5D–S5G; Table
S6). The cell-cycle module included multiple cell-cycle check-
point proteins involved in the G1/S-phase transition (CDKN1B,
SKP2), S-phase regulatory elements (MCM4, MCM6), and the
G2/M phase (CDK1, TK1, CDC20) (Figure S5D), with phosphor-
ylation of CDC20 representing another mechanism of mitotic-ar-
rest (Hein and Nilsson, 2016). Interestingly, we observed tumors
with genomic instability that correlated with this module, as well
as phospho-events involved in DNA damage response (e.g.,
FANCD2, PSME3, CLSPN, and BRCA1) (Figures 5D and S5D),
representing a mechanism by which a subset of tumors engage
cellular processes in response to loss of genomic fidelity. The
angiogenesis module included multiple elements associated
with VEGF-response (ELK3, ERG), Notch-associated signaling
(LDB2, SOX18), and vasculature development (PECAM-1,
CCM2L) (Figure S5E). This module was inversely correlated
with BAP1 and chromosome 14 loss and associated with
lower-grade tumors (Figure S5G). Our phosphoproteomic anal-
ysis thus identified multiple signal transduction pathways acti-
vated in tumors and provided evidence for expanding treatment
selection beyond the current FDA-approved therapies targeting
VEGF and mTOR (Figure 5B; Hsieh et al., 2018b).
Characterization of Immune Infiltration in ccRCC
To gain insight into features of immune infiltration in ccRCC, we
analyzed the transcriptomic profiles of 103 tumors and 72 NATs
and deconvoluted immune, stromal, and microenvironmental
cell gene signatures using xCell (Aran et al., 2017). These molec-
ularly based cell-type classifications were supported by histo-
pathological assessment, DNA promoter methylation-based
deconvolution analysis, and ESTIMATE analysis (Yoshihara
et al., 2013), with the latter showing a Pearson correlation higher
than 0.75 between protein andmRNAdata for immune- and stro-
mal-derived signatures (Figures S6A and S6B; Table S7).
ESTIMATE generated RNA-seq stromal and immune signatures
in this cohort were comparable to those observed in TCGA
ccRCC and Genotype-Tissue Expression (GTEx) kidney-cortex
datasets (Figure S6C). Consensus clustering of the cell signa-
tures identified two NAT subtypes with distinct enrichment of
cell signatures relative to ccRCC tumor tissues and four ccRCC
tumor subtypes (Figure 6A). The latter were discriminated by the
presence or absence of specific cell types related to immune
(CD8+ T cells, macrophages, dendritic cells) and stromal (fibro-
blast, endothelial) signatures. Adopting general features of im-
mune-based groupings described previously (Chen and Mell-
man, 2017) and incorporating transcriptomic and proteomic
features, we defined four tumor subtypes in this ccRCC cohort:
(1) CD8+ inflamed, (2) CD8 inflamed, (3) VEGF immune desert,
and (4) metabolic immune desert (Figures 6B and S6D; Table
S7). These subtypes were characterized by unique genomic al-
terations and tumor microenvironment (TME) signatures and
discriminating signaling pathways that could be leveraged to
predict therapeutic response (Figures 6B, 6C, and 6E).
CD8+ inflamed tumors were characterized by a high degree of
CD8+ T cell infiltration (t test adjusted p < 0.05) (Figure S6D),
increased expression of the immune evasion markers PD1,
PD-L1, PD-L2, and CTLA4 (t test adjusted p < 0.05), and high
frequency of chromosome 14 loss (chi-square test p < 0.05) (Fig-
ures 6A–6C). Corresponding to the elevated CD8+ T cell
presence was a higher frequency of BAP1 mutations, a feature
previously associated with increased immune infiltration in a kid-
ney cancer xenograft model (Wang et al., 2018b). Proteomic
analysis showed upregulation of CD38 expression and pathways
involved in antigen processing/presentation (APM) and inter-
feron-g signaling (Fisher’s exact test adjusted p < 0.05) (Figures
6B and S6E; Table S7). Phosphoproteomic analysis confirmed
active interferon-g signaling via elevated phosphorylation of
the downstream effector STAT1 (t test adjusted p < 0.05) (Fig-
ure 6B). Interferon-g signaling has been shown to regulate PD-
L1 expression in cancer cells (Chen et al., 2012; Garcia-Diaz
et al., 2017), and the combination of increased CD38 protein
and mRNA signature (PD-L1, PD-L2, and CTLA4) associated
with T cell exhaustion are representative of multiple mechanisms
of immune evasion in this tumor type, with implications for im-
mune checkpoint therapy (Chen et al., 2018; Sade-Feldman
et al., 2018).
CD8 inflamed tumors were characterized by an innate im-
mune signature, evidenced by dendritic and macrophage cells
in the TME compared to the VEGF andmetabolic immune desert
groups and by increased complement and coagulation cascade
protein expression (Fisher’s exact test adjusted p < 0.05) (Fig-
ures 6A, 6B, and S6D; Table S7). A fibroblast signature that
included elevated PDGFRA, extracellular matrix (ECM) and
EMT-associated protein abundance, and expression of cancer
associated fibroblasts (CAFs) features (POSTN protein and
gene FAP mRNA) (t test adjusted p < 0.05) was a unique feature
of the CD8 inflamed tumor subtype (Figures 6A, 6B, and S6E;
Shiga et al., 2015; Ziani et al., 2018). Together, these associated
Figure 5. Phospho-Substrates with Associated Kinases and a Network Module Specific to Phospho-Tumor Data
(A) Ranked phospho-substrate events of kinases with inhibitors and fold-change at global- and phospho-levels for kinases and substrates, respectively.
(B) Pathways based on the selected phospho-substrates and kinases, with relevant drugs shown by targets (red). Current FDA-approved drugs for ccRCC (gray).
(C) Pairwise correlation of nodes at multi-omics levels of ‘‘cell cycle’’ co-expression network module.
(D) Heatmap of ‘‘cell cycle’’ module expression with grade, BAP1 and chromosome 14 loss, and genome instability distribution annotated.
See also Figure S5 and Tables S1 and S6.
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pathways are representative of TME-tumor crosstalk, with PDGF
signaling driving fibroblast recruitment and activation, and CAFs
subsequently inducing an EMT-phenotype in tumors (Gascard
and Tlsty, 2016; Seppä et al., 1982). Interestingly, PD-L2
mRNA levels were elevated independent of PD-L1 expression
(Figure 6B), suggesting a CAF-mediated mechanism of T cell
Figure 6. Immune-Based Subtyping of ccRCC Tumors
(A) Transcriptome-based deconvolution of mRNA transcript cell signatures in 103 ccRCC tumors and 72 NATs using xCell.
(B) Molecular characteristics (transcriptomic, proteomic) stratified tumors into four immune subtypes: CD8+ inflamed (red), CD8 inflamed (blue), VEGF immune
desert (yellow), metabolic immune desert (green), and NATs into two subtypes (pink and gray).
(C) Proportion of BAP1 mutation, PBRM1 mutation, chromosome 14 loss, and chromosome 7 gains within each of the immune groups.
(D) Proportion of high tumor grade tumors (i.e., grade 3 and grade 4) in each of the immune groups for CPTAC and TCGA datasets. High-grade tumors were
significantly enriched in CD8+ inflamed group compared to VEGF immune desert group.
(E) Density contours of immune and stroma scores of each immune subtype. Pathways upregulated based on RNA-seq and global proteomics data are labeled
with ‘‘R’’ or ‘‘P,’’ respectively.
See also Figure S6 and Tables S1 and S7.
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death via PD-L2 antigen presentation (Lakins et al., 2018). Inde-
pendently, increased mRNA expression of ENTPD1 (CD39) and
NT5E (CD73) in the CD8 inflamed tumor subtype could signal
an adenosine-rich TME (Antonioli et al., 2013), further contrib-
uting to CD8+ T cell exclusion in these tumors (Figures 6B
and S6D).
CD8 inflamed tumors and VEGF immune desert tumors
shared several features including an elevated stromal score (t
test adjusted p < 0.05) and enrichment of endothelial cells (t
test adjusted p < 0.05 – VEGF immune desert) (Figures 6A and
6B; Table S7). Interestingly, these tumor subtypes had a higher
frequency of chromosome 7 gain and lower frequency of chro-
mosome 14 loss, with the latter feature inversely correlated
with endothelial cell presence (Figures 6A and 6C). Although
angiogenic signaling was elevated in both subtypes (Fisher’s
exact test adjusted p < 0.05), angiogenesis and platelet degran-
ulation were higher in CD8 inflamed tumors (Fisher’s exact test
adjusted p < 0.05) and corresponded to upregulation of the
PDGF-related signaling pathway (Table S7). In contrast, higher
expression of SUMOylation (protein level) and Wnt/b-catenin,
RAP1, and Notch signaling pathways (mRNA level) were
observed in VEGF immune desert tumors and corresponded to
the highest endothelial cell signature (t test adjusted p < 0.05)
(Figures 6B and S6E). The differential expression of VEGFR1
(FLT1) (t test adjusted p < 0.05) and multiple angiogenic-related
signaling pathways may be representative of distinct mecha-
nisms of endothelial cell recruitment and tumor vasculature for-
mation between the two subtypes (Birdsey et al., 2015; Cao,
2013; Chrzanowska-Wodnicka, 2013; Hellström et al., 2007;
Zhou et al., 2018; Zhu et al., 2017).
Metabolic immune desert tumors displayed low immune, stro-
mal, and microenvironment scores (t test adjusted p < 0.05), an
elevated MYC target mRNA signature (Fisher’s exact test
adjusted p < 0.05), increased mTOR signaling (Fisher’s exact
test adjusted p < 0.05), and a unique metabolic profile that
included elevated mitochondrial, OXPHOS, glycolysis protein
expression (Fisher’s exact test p < 0.05), and PKM mRNA
expression (t test adjusted p < 0.05) (Figures 6B and S6E; Table
S7). Previous reports have established a relationship between
HIF-2a and MYC-induced transcription in renal carcinomas
(Gordan et al., 2007a, 2008), with MYC regulation of metabolism
functioning in concert with and independent of HIF-1 signaling
(Gordan et al., 2007b). Further contributing to this unique meta-
bolism signature was the increased expression of PRDX4 (t test
adjusted p < 0.05) (Figure 6B), which has been shown to impair
the binding of HIF-1a/2a to the hypoxia response element in
select glycolytic genes (SLC2A3, PDK3, GPI) (Luo et al., 2016).
The minimal presence of any immune cells in metabolic immune
desert tumors is particularly striking and supports the hypothesis
that a hypoxic, nutrient-poor microenvironment can be immuno-
suppressive (Anderson et al., 2017; Mgrditchian et al., 2014).
This analysis discriminated four subtypes of ccRCC and
linked unique cellular pathways to observed TME compositions,
with select protein features validated using an orthogonal mass
spectrometry approach (Figures 6A, 6E, and S6D; Table S7).We
hypothesized that the delineated molecular signatures may
predict patient responses to select therapies and survival. To
examine the former, we characterized tumors within each sub-
type using two gene signatures that have been previously asso-
ciated with patient response to immune checkpoint and anti-
VEGF therapies (T-effector [Teff] and angiogenesis [Angio]),
respectively (McDermott et al., 2018). CD8+ inflamed tumors
displayed an elevated Teff signature relative to other tumor
types, while VEGF immune desert tumors displayed an elevated
Angio signature (Figure S6F). The remaining two subtypes dis-
played aminimal Teff signature but had amoderate Angio signa-
ture, suggesting a potential response to therapeutics targeting
VEGF signaling. Leveraging the gene signatures from our sub-
types, we explored the TCGA dataset and observed similar dis-
tribution patterns of tumor grade and CD8+ T cell, endothelial,
and fibroblast cell composition (Figures 6D and S6G; Table
S7). Patient stratification based on the four subtypes revealed
that VEGF immune desert tumors were associated with
improved patient survival, while CD8+ Inflamed tumors were
associated with poor patient outcome (log-rank test adjusted
p < 0.05) (Figure S6H). The latter result reflects the aggregation
of multiple features in the CD8+ Inflamed subtype that are
considered as poor prognosticators in ccRCC, including higher
frequency of BAP1 mutations (chi-square test adjusted p <
0.05), increased proportion of higher grade tumors, and
increased PD-1/PD-L1 expression (t test adjusted p < 0.05).
We did not detect an association of tumor mutational burden
or neoantigen load with any of these immune subtypes (Table
S7), confirming previous reports that indicate that these fea-
tures do not correlate with ccRCC prognosis (Matsushita
et al., 2016; McDermott et al., 2018).
Proteome Inter-Tumoral Heterogeneity of ccRCC
Tumor grade is an important prognosticator in ccRCC, which is
often associated with higher-stage and larger tumors (Ishigami
et al., 2014). Multivariate analysis integrating clinical features
and CPTAC ‘‘omics’’ data found that numerous genes within
each data typewere associatedwith immune and stromal scores
and with tumor grade (Benjamini-Hochberg adjusted p < 0.10;
Figure S7A). Further investigation of these genes revealed
distinct pathways associated with tumor grade. In high-grade tu-
mors, translation, mTOR signaling, and EMT were increased at
the mRNA and protein levels. Other cellular pathways displayed
disparate upregulation at the transcriptomic and proteomic
levels. For example, increased mRNA levels were associated
with cell-cycle regulation and DNA repair, while increased
OXPHOS and N-linked glycosylation were detected only at the
protein level (Figures 7A and S7B; Table S5). In contrast, low-
grade tumors displayed increased expression of receptor tyro-
sine kinase, RAS, MAPK, Notch, and RAP1 cell signaling
pathways at both the mRNA and protein levels (Wilcoxon rank-
sum test, Benjamini-Hochberg adjusted p < 0.01; Figures 7A
and S7B; Table S5). Low-grade tumors showed increased
protein expression of transcription-related processes (e.g., chro-
matin reorganization) that was not captured at the transcript level
(Wilcoxon rank-sum test, Benjamini-Hochberg adjusted p <
0.01; Figure 7A; Table S5). The divergence of cellular processes
between high- and low-grade tumors reflects the disparate tu-
moral needs, with higher grade tumors upregulating mecha-
nisms to adapt to increased genomic alterations and a changing
tumor microenvironment.
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To determine ccRCC inter-tumor heterogeneity of the CPTAC
cohort, we constructed an unbiased proteomic grouping of
ccRCC. Three major proteomic ccRCC groups emerged from
this analysis (ccRCC1-3), which were discriminated by seven
major protein clusters (Figure 7B; Table S5). Tumors in ccRCC2
had a higher degree of protein expression associated with
innate immunity and platelet degranulation (adjusted p <
0.05), while those in ccRCC3 displayed increased protein
expression associated with glycolysis, mTOR signaling, and
hypoxia (adjusted p < 0.05). ccRCC2 and ccRCC3 were associ-
ated with lower tumor grade (p < 0.01 and p < 0.02, respec-
tively), while only ccRCC2 was associated with lower stage
(p < 0.001). Tumors in ccRCC1 presented with higher grade
(p < 0.001) and stage (p < 0.01), characterized by elevated
adaptive immune response, N-linked glycosylation, OXPHOS
protein expression, and fatty acid metabolism (adjusted p <
0.05). Tumors in ccRCC3 displayed a higher frequency of
PBRM1 mutations (p < 0.05), whereas those in ccRCC1 had a
higher frequency of BAP1mutations (p < 0.0001), CIMP+ status
Figure 7. Proteomic Inter-Tumor Heteroge-
neity of ccRCC and Associated Functional
Pathways
(A) Cellular pathways (right) with positive (red) or
negative (blue) associations with grade (adjusted
p < 0.05) at protein or mRNA level (left). Heatmap
of protein expression associated with high- and
low-grade tumors (center) (Benjamini-Hochberg
adjusted p < 0.05).
(B) Heatmap of global proteomic abundances. For
subtype identification, protein features (n = 3,567)
were selected based on highest variance. Color
indicates Z score of protein in each sample: red is
increased, blue is decreased. Clinical and molec-
ular features are indicated above the heatmap.
Cluster-derived modules are annotated according
to pathway enrichment using Hallmark Gene
signature, REACTOME, and KEGG ontologies
(adjusted p < 0.05).
See also Figure S7 and Tables S1 and S5.
(p < 0.007), and genomic instability (p <
0.0001) (Figure 7B). As highlighted in
our immune analysis, ccRCC tumors
had variable TME compositions, with im-
mune and stromal signatures impacting
observed protein expression patterns
(Figure S7A). The distribution of the im-
mune subtypes across the proteomic
groupings contributed to the discrimi-
nating gene clusters described in Fig-
ure 7B that were also delineated in the
immune-based subtyping of ccRCC (Fig-
ure 6B), capturing the more dominant
molecular signatures of CD8+ inflamed
(interferon-g signaling), CD8 inflamed
(platelet degranulation), and VEGF im-
mune desert (hypoxic signaling) tumors,
which had a higher prevalence in
ccRCC1 (p < 5.0 e07), ccRCC2 (p < 6.0 e05), and ccRCC3
(p < 0.0001), respectively.
DISCUSSION
This comprehensive proteogenomic characterization of ccRCC
provides insight into the differential impact of underlying
genomic and epigenomic events on the transcriptome, prote-
ome, and phosphoproteome. The integration of chromosome-
level alterations and comparative, multi-level profiling of treat-
ment-naive tumors and NATs connects genomic aberrations to
active mechanisms that drive ccRCC tumorigenesis. The identi-
fication of a subset of ccRCC patients who display genomic
instability could have clinical utility that warrants further investi-
gation, as this group may have worse prognosis and benefit
from continual surveillance post-treatment. The trans-effects of
chromosome 3p fully capture the dysregulated VHL/HIF-1 axis
that is a hallmark of ccRCC, while the widespread translocation
events involving chromosome 3 observed in this study and
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others (Mitchell et al., 2018; Pavlovich et al., 2003) portray
ccRCC as a disorder defined by genomic rearrangements.
Our analysis supports and elaborates on the metabolic shift
that occurs within ccRCC tumors, illustrated at the protein level
by the upregulation of glycolysis and the corresponding downre-
gulation of the Krebs cycle and the electron transport chain
(OXPHOS) associated with the Warburg effect. Notably, the
downregulation of components of the Krebs cycle and themajor-
ity of the nuclear-encoded OXPHOS proteins were not observed
at the mRNA level and would have not been reported by RNA-
seq analysis alone. This finding is significant, as recent large-
scale ccRCC studies have focused on mRNA expression data
to depict the metabolic shift in ccRCC and have evaluated tran-
scriptomic signatures to stratify patients with more aggressive
disease (Chen et al., 2016a; Creighton et al., 2013). HIF1-
signaling has been shown to decrease OXPHOS activity through
multiple mechanisms (Hervouet et al., 2008; Papandreou et al.,
2006). Interestingly, our proteomic analysis and previous meta-
bolic profiling of ccRCC show evidence of late-stage tumors
upregulating the OXPHOS pathway relative to earlier-stage tu-
mors (Hakimi et al., 2016) and may reflect the dysregulation of
HIF-1a expression resulting from 14q loss or the aberrant
methylation profiles associated with CIMP+ status. The mainte-
nance of OXPHOS transcription levels similar to those seen in
normoxic cells may provide a mechanism for rapid induction of
OXPHOS activity when it is advantageous to fulfill tumor energy
requirements. This hypothesis warrants deeper exploration and
expanded investigation in other cancer types.
Current first-line therapies for advanced ccRCC target VEGF
and mTOR (Escudier et al., 2007a, 2007b; Hudes et al., 2007;
Motzer et al., 2007, 2008; Sternberg et al., 2010), with ongoing
exploration of immune checkpoint inhibitors (Atkins and Tannir,
2018). Through investigation of transcriptomic, proteomic, and
phosphoproteomic signatures of treatment-naive tumors, we
propose a rational stratification of ccRCC patients for personal-
ized therapeutic interventions. Immune-based subtyping of
ccRCC tumors via deconvolution of cell composition identified
TME and cellular pathways that delineated patients who
displayed a pro-angiogenic phenotype from those with an im-
mune-evasive phenotype. With evidence demonstrating the
lack of efficacy of anti-VEGF therapy in patients with elevated
levels of immune checkpoint signatures (Hara et al., 2017; Shin
et al., 2015) and preliminary clinical studies showing encour-
aging results when treating RCC using PD-1/CTLA4-targeting
therapies (Motzer et al., 2018), it is vital to identify theranostic
markers to improve patient outcome and overall survival. How-
ever, mechanisms that drive the observed differences in TME
signatures warrant further exploration. Our results support
recent reports that tumor mutational burden or neoantigen load
may not be associated with immune infiltration or response to
immune checkpoint therapy in ccRCC (Matsushita et al., 2016;
McDermott et al., 2018), although alternative explanations,
such as endogenous retroviral expression, were not examined
in our study (Panda et al., 2018; Smith et al., 2018). Independent
of current first-line regimens and immune checkpoint inhibition,
the ubiquitous activation of EGFR and downstream signaling
cascades (MAPK1), as well as cell-cycle checkpoint regulation
(WEE1-CDK1) revealed by our phosphoproteomic analysis, pro-
vide additional therapeutic targets that have been evaluated
extensively in other cancer types but minimally in ccRCC (As-
cierto et al., 2013; Huang et al., 2008;Matheson et al., 2016; Rav-
aud et al., 2008). Application to ccRCC would be especially
important given our identification of a subset of ccRCC tumors
that are predicted or shown to be immune checkpoint/VEGF
non-responders (Beuselinck et al., 2015; Maroto et al., 2017)
that may benefit from therapies that activate anti-tumor T cell
expansion (Naing et al., 2018) or combinatorial therapeutic ap-
proaches, such as concurrent cell-cycle checkpoint and mTOR
inhibition.
Overall, this study reveals unique biological insights that are
gained only when combining complementary proteomic and
genomic analyses that link the functional consequences of
genomic aberrations with proteomic outcomes. The integration
of comprehensive genomic, epigenomic, transcriptomic, pro-
teomic, and phosphoproteomic measurements for tumors
and corresponding NATs provides an invaluable bioinformatic
resource for the deeper examination of ccRCC tumorigenesis.
Our multi-level ‘‘omics’’ analysis identifies underlyingmolecular
mechanisms that are not fully captured at the genomic and
transcriptomic levels and defines proteomic, phosphoproteo-
mic, and immune signatures necessary to stratify ccRCC
patients, with the goal of developing rational therapeutic
interventions.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-CD8 (C8/144B) Cellmarque Catalog #108M-96; RRID: AB_1158208
Rabbit monoclonal anti-CD4 (SP35) Roche Catalog #790-4423
Liquid Concentrated Monoclonal Antibody
anti-CD163
Leica Biosystems Catalog #NCL-L-163; RRID: AB_2756375
Biological Samples
Primary tumor samples See Experimental Model and
Subject Details
N/A
Chemicals, Peptides, and Recombinant Proteins
Aprotinin Sigma Catalog: A6103
Leupeptin Roche Catalog: 11017101001
Phenylmethylsulfonyl fluoride Sigma Catalog:93482
Sodium fluoride Sigma Catalog: S7920
Phosphatase Inhibitor Cocktail 2 Sigma Catalog: P5726
Phosphatase Inhibitor Cocktail 3 Sigma Catalog: P0044
Urea Sigma Catalog: U0631
Tris(hydroxymethyl)aminomethane Invitrogen Catalog: AM9855G
Ethylenediaminetetraacetic acid Sigma Catalog: E7889
Sodium chloride Santa Cruz Biotechnology Catalog: sc-295833
PUGNAc Sigma Catalog: A7229
Dithiothretiol ThermoFisher Scientific Catalog: 20291
Iodoacetamide ThermoFisher Scientific Catalog: A3221
Sequencing grade modified trypsin Promega Catalog: V511X
Lysyl endopeptidase, aass spectrometry grade Wako Chemicals Catalog: 125-05061
Formic acid Fisher Chemical Catalog: A117-50
Reversed-phase C18 SepPak Waters Catalog: WAT054925
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Alfa Aesar Catalog: J63218
Tandem mass tags – 10plex ThermoFisher Scientific Catalog: 90110
Trifluoroacetic acid Sigma Catalog: 302031
Ammonium Hydroxide solution Sigma Catalog: 338818
Hydroxylamine solution Aldrich Catalog: 467804
Ni-NTA agarose beads QIAGEN Catalog: 30410
Iron (III) chloride Sigma Catalog:451649
iVIEW DAB Detection Kit Roche Catalog: 760-091
Bond Polymer Refine Detection Kit Leica Biosystems Catalog: DS9800
Critical Commercial Assays
TruSeq Stranded Total RNA Library Prep Kit
with Ribo-Zero Gold
Illumina Catalog: RS-122-2301
Infinium MethylationEPIC Kit Illumina Catalog: WG-317-1003
Nextera DNA Exosome Kit Illumina Catalog: 20020617
KAPA Hyper Prep Kit, PCR-free Roche Catalog: 07962371001
BCA Protein Assay Kit ThermoFisher Scientific Catalog: 23225
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
PhosphoSitePlus Hornbeck et al., 2015 https://www.phosphosite.org
GTEx Ardlie et al., 2015 https://gtexportal.org/home/
TCGA - ccRCC Creighton et al., 2013 https://portal.gdc.cancer.gov/
Software and Algorithms
methylationArrayAnalysis (version 3.9) Maksimovic et al., 2016 https://master.bioconductor.org/packages/release/
workflows/html/methylationArrayAnalysis.html
Illumina EPIC methylation array (3.9) Fortin et al., 2017 https://bioconductor.org/packages/release/data/
annotation/html/IlluminaHumanMethylationEPICanno.
ilm10b2.hg19.html
VarDict Lai et al., 2016 https://github.com/AstraZeneca-NGS/VarDict
Strelka2 Kim et al., 2018 https://github.com/Illumina/strelka
MUTECT2 Cibulskis et al., 2013 https://software.broadinstitute.org/gatk/
documentation/tooldocs/3.8-0/org_broadinstitute_
gatk_tools_walkers_cancer_m2_MuTect2.php
VarScan2.3.8 Koboldt et al., 2012 http://varscan.sourceforge.net
Pindel0.2.5 Ye et al., 2009 http://gmt.genome.wustl.edu/packages/pindel/
CNVEX Marcin Cieslik Lab https://github.com/mctp/cnvex
CRISP Marcin Cieslik Lab https://github.com/mcieslik-mctp/crisp-build
Proteowizard Kessner et al., 2008 http://proteowizard.sourceforge.net/
MSFragger Kong et al., 2017 https://msfragger.nesvilab.org/
Philosopher Alexey Nesvizhskii Lab https://philosopher.nesvilab.org/
PeptideProphet Keller et al., 2002 http://peptideprophet.sourceforge.net/
ProteinProphet Nesvizhskii et al., 2003 http://proteinprophet.sourceforge.net/prot-proph.pdf
PTMProphet Deutsch et al., 2015 http://www.tppms.org/tools/ptm/
TMT-Integrator Alexey Nesvizhskii Lab https://github.com/Nesvilab/TMT-Integrator
DIA-Umpire Tsou et al., 2015 https://github.com/Nesvilab/DIA-Umpire
msproteomicstools http://msproteomicstools.
roestlab.org/
https://github.com/msproteomicstools
ComBat (v3.20.0) Johnson et al., 2007 https://bioconductor.org/packages/release/bioc/
html/sva.html
DreamAI Pei Wang Lab https://github.com/WangLab-MSSM/DreamAI
GISTIC2.0 Mermel et al., 2011 ftp://ftp.broadinstitute.org/pub/GISTIC2.0/
GISTIC_2_0_23.tar.gz
iProFun Song et al., 2019 https://github.com/WangLab-MSSM/iProFun
ESTIMATE Yoshihara et al., 2013 https://bioinformatics.mdanderson.org/public-
software/estimate/
WebGestaltR Wang et al., 2017 http://www.webgestalt.org/
Joint Random Forest Petralia et al., 2016 https://github.com/WangLab-MSSM/ptmJRF
GSVA Hänzelmann et al., 2013 https://bioconductor.org/packages/release/bioc/
html/GSVA.html
TCGAbiolinks Colaprico et al., 2016 http://bioconductor.org/packages/release/bioc/
html/TCGAbiolinks.html
Cytoscape Shannon et al., 2003 https://cytoscape.org/
TSNet Petralia et al., 2018 https://github.com/WangLab-MSSM/TSNet
xCell Aran et al., 2017 http://xcell.ucsf.edu/
CPTAC Network Exploration Portal Pei Wang Lab http://ccrcc.cptac-network-view.org/
CPTAC Data Viewer Pei Wang Lab http://ccrcc.cptac-data-view.org/
iCAVE Liluashvili et al., 2017 http://labs.icahn.mssm.edu/gumuslab/software
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LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources should be directed to and will be
fulfilled by the Lead Contact, Hui Zhang (huizhang@jhu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
A total of 110 participants, with an age range of 30-90, were included in this study. This cohort contained males (n = 81) and females
(n = 29) and reflects the gender distribution of clear cell renal cell carcinoma (ccRCC) (Creighton et al., 2013). Only histopathologically
defined adult ccRCC tumors were only included in the analysis. Institutional review boards at each Tissue Source Site (TSS) reviewed
protocols and consent documentation, in adherence to Clinical Proteomic Tumor Analysis Consortium (CPTAC) guidelines.
Clinical Data Annotation
Clinical data were obtained from TSS and aggregated by the Biospecimen Core Resource (BCR, Van Andel Research Institute
(Grand Rapids, MI)). Data forms were stored as Microsoft Excel files (.xls). Clinical data can be accessed and downloaded from
the CPTAC Data Portal at https://cptac-data-portal.georgetown.edu/cptac/documents/S044_CPTAC_CCRCC_Discovery_Cohort_
Clinical_Data_r1_Sept2018.xlsx. Patients with any prior history of other malignancies within twelvemonths or any systemic treatment
(chemotherapy, radiotherapy, of immune-related therapy) were excluded from this study. Demographics, histopathologic informa-
tion, and treatment details were collected and summarized in Table S1. The characteristics of the CPTAC ccRCC cohort reflect
the general incidence of ccRCC (Creighton et al., 2013), including patient age distributions [30-49 (17.4%), 50-69 (60.6%), and >
70 (22.0%)], grade distributions [G1 (5.5%), G2 (48.6%), G3 (37.6%), and G4 (8.3%)], and stage distributions [I (46.8%), II
(11.9%), III (30.3%), and IV (11.0%)].
METHOD DETAILS
Specimen Acquisition
The tumor, adjacent normal tissue and whole blood samples used in this manuscript were prospectively collected for the CPTAC
project. Biospecimens were collected from newly-diagnosed patients with ccRCC who were undergoing surgical resection and
had received no prior treatment for their disease, including radiotherapy or chemotherapy. All cases had ccRCC histology but
were collected regardless of histologic grade or surgical stage. Cases were then graded using the Fuhrman Nuclear Grading
System and staged using the AJCC cancer staging system 7th edition (Edge et al., 2010). Tumors specimens weighed between
125 and 3,000 mg. For most cases, three to four tumor specimens were collected. Each tissue specimen endured cold ischemia
for 30 minutes or less prior to freezing in liquid nitrogen. The specimens were collected with an average total ischemic time of fifteen
minutes from resection/collection to freezing. Specimens were either flash-frozen in liquid nitrogen or embedded in optimal cutting
temperature (OCT) medium, with histologic sections obtained from top and bottom portions for review. Each case was reviewed by a
Continued
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MODMatcher Yoo et al., 2014 https://github.com/integrativenetworkbiology/
Modmatcher
ConsensusClusterPlus Monti et al., 2003; Wilkerson
and Hayes, 2010
http://bioconductor.org/packages/release/bioc/
html/CancerSubtypes.html
OmicsX Pan et al., 2019 http://bioinfo.wilmer.jhu.edu/OmicsX/
Omic-Sig Lih et al., 2019 https://github.com/hzhangjhu/Omic-Sig
OmicsOne Hu et al., 2019 https://github.com/HuiZhangLab-JHU/OmicsOne
pyQUILTS (v1.0) Ruggles et al., 2016 http://openslice.fenyolab.org/cgi-bin/pyquilts_cgi.pl
MS-GF+ Kim and Pevzner, 2014 https://github.com/MSGFPlus/msgfplus
NeoFlow Bing Zhang Lab https://github.com/bzhanglab/neoflow
netMHCpan Jurtz et al., 2017 http://www.cbs.dtu.dk/services/NetMHCpan/
Optitype Szolek et al., 2014 https://github.com/FRED-2/OptiType
Customprodbj Bing Zhang Lab https://github.com/bzhanglab/customprodbj
PDV Li et al., 2019 https://github.com/wenbostar/PDV
PepQuery Wen et al., 2019 http://pepquery.org
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board-certified pathologist to confirm the assigned pathology. The top and bottom sections were required to contain an average of
80% tumor cell nuclei with less than 20% necrosis. Specimens were shipped overnight from the TSS to the BCR using a cryoport that
maintained an average temperature of less than140C. At the BCR, the specimens were confirmed by pathology qualification and
prepared for genomic, transcriptomic, and proteomic analyses. Selected specimens were cryopulverized, and material was
aliquoted for subsequent molecular characterization. Genomic DNA and total RNA were extracted and sent to the genome
characterization centers (GCC). The DNA sequencing and methylation analyses were performed at the Broad Institute (Cambridge,
MA) and RNA sequencing was performed at the University of North Carolina (Chapel Hill, NC). Material for proteomic analyses
was sent to the Proteomic Characterization Center (PCC) at Johns Hopkins Medical Institutions of Johns Hopkins University
(Baltimore, MD)
Genomic and Transcriptomic Sample Preparation and Data Acquisition
Sample Processing for Genomic DNA and total RNA Extraction
Our study sampled a single site of the primary tumor. All DNA and RNA were isolated using a co-isolation protocol in which nucleic
acids were isolated from the same cryopulverized aliquot that was used for both proteomics and genomics. Tumor samples were
from surgical resections due to the requirement to process a minimum of 125mg of tumor issue and 50mg of adjacent normal tissue.
RNA and DNA were extracted from tumor and adjacent normal specimens using QIAGEN’s QIAsymphony DNA Mini Kit and
QIAsymphony RNA Kit. Genomic DNA was also isolated from peripheral blood (3-5 mL) to serve as matched benign reference
material. The Qubit dsDNA BR Assay Kit was used with the Qubit 2.0 Fluorometer to determine the concentration of dsDNA in
an aqueous solution. A sample that passed quality control and produced sufficient DNA yield various genomic assays was sent
for genomic characterization. RNA quality was quantified using the NanoDrop 8000 and quality was assessed using Agilent
Bioanalyzer. A sample that passed RNA quality control and had a minimum RNA integrity Number (RIN) score of 8 was subjected
to RNA sequencing.
Whole Exome Sequencing Methods
Library Construction
Library construction was performed as described in Fisher et al. (2011), with the following modifications: initial genomic DNA input
into shearing was reduced from 3 mg to 250 ng in 50 mL of solution. For adaptor ligation, Illumina paired end adapters were replaced
with palindromic forked adapters obtained from Integrated DNA Technologies, with unique dual-indexed molecular barcode
sequences to facilitate downstream pooling. Kapa HyperPrep reagents were used in a 96-reaction kit format for end repair/A- tailing,
adaptor ligation, and library enrichment PCR. In addition, during the post-enrichment SPRI cleanup, elution volume was reduced to
30 mL to maximize library concentration followed by a vortexing step to maximize the amount of template eluted.
In-solution Hybrid Selection
Following library construction, products were pooled into groups of up to 96 samples. Hybridization and capture were performed
using the relevant components of Illumina’s Nextera Exome Kit and following the manufacturer’s recommended protocol, with a
few exceptions. First, all libraries within a library construction plate were pooled prior to hybridization. Second, to facilitate automa-
tion the Midi plate from Illumina’s Nextera Exome Kit was replaced with a skirted PCR plate. All hybridization and capture steps were
automated utilizing the Agilent Bravo liquid handling system.
Preparation of Libraries for Cluster Amplification and Sequencing
After post-capture enrichment, library pools were quantified by qPCR using a kit obtained from KAPA Biosystems with probes
specific to the ends of the adapters. The assay was automated on the Agilent Bravo liquid handling system. Based on qPCR
quantification, libraries were normalized to 2 nM.
Cluster Amplification and Sequencing
Cluster amplification of DNA libraries was performed according to the manufacturer’s protocol (Illumina) using exclusion amplifica-
tion chemistry and flowcells. Flowcells were sequenced utilizing Sequencing-by-Synthesis chemistry. The flowcells are then
analyzed using RTA v.2.7.3 or a later version. Each pool of whole exome libraries was sequenced on paired 76-cycle runs with
two eight-cycle index reads across the number of lanes necessary to meet coverage for all libraries in the pool. Pooled libraries
were processed using HiSeq4000 as paired end runs to achieve a minimum of 150x on-target coverage per library. The raw Illumina
sequence data were demultiplexed and converted to FASTQ files, and adaptor and low-quality sequences were trimmed. The raw
reads were mapped to the hg38 human reference genome. The validated Binary Alignment Map (BAM) files were used for down-
stream analysis and variant calling. FASTQ files of all reads were then uploaded to the Genomic Data Commons (GDC) repository.
Whole Genome Sequencing, PCR-Free
Preparation of Libraries for Cluster Amplification and Sequencing
Input genomic DNA (350 ng in 50 mL) was acoustically sheared using a Covaris focused-ultrasonicator (385 bp fragment range).
Following shearing, an additional size selection was performed using a SPRI cleanup. Library preparation was performed using
KAPA Hyper Prep without amplification module (KAPA Biosystems) with palindromic forked adapters containing unique eight-
base index sequences embedded within the adaptor (Integrated DNA Technologies). Libraries were quantified using quantitative
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PCR (KAPA Biosystems), with probes specific to the ends of the adapters. The assay was automated on the Agilent Bravo liquid
handling system. Based on qPCR quantification, libraries were normalized to 1.7 nM and pooled into 24-plexes.
Cluster Amplification and Sequencing (HiSeqX)
Sample pools were combined with HiSeqX Cluster Amp Regents EPX1, EPX2 and EPX3 into single wells on a strip tube using the
Hamilton Starlet Liquid Handling system. Cluster amplification of the templates was performed according to the manufacturer’s
protocol (Illumina) with the Illumina cBot. Flowcells were sequenced for a minimum of 15x coverage on HiSeqX utilizing
sequencing-by-synthesis to produce 151 base pair paired-end reads. Outputs from Illumina software were processed by the Picard
data-processing pipeline to yield BAM files containing demultiplexed, aggregated aligned reads. All sample information tracking was
performed by automated LIMS messaging. FASTQ files of all reads were then uploaded to the GDC.
Illumina Infinium MethylationEPIC BeadChip Array
The MethylationEPIC array uses an eight-sample version of the Illumina BeadChip that captures > 850,000 methylation sites per
sample. 250 ng of DNA was used for bisulfite conversion using the Infinium MethylationEPIC BeadChip Kit. The EPIC array includes
sample plating, bisulfite conversion, and methylation array processing. After scanning, the data were processed through an auto-
mated genotype calling pipeline, generating raw idat files and a sample sheet. For 109 out of the 110 samples, a sufficient amount
of material was obtained to perform methylation profiling. Two out of the 109 samples showed a missing rate greater than 95% and
were excluded from all downstream analyses.
RNA Sequencing
Quantitation and Quality Assessment QC of total RNA Samples
All RNA analytes were assayed for RNA integrity, concentration, and fragment size. Samples for total RNA-seq were quantified on a
TapeStation system (Agilent). Samples with RINs > 8.0 were considered to be of high quality and were processed further.
Total RNA-seq Library Construction
Total RNA-seq libraries were generated using 300 ng of total RNA, analyzed using the TruSeq Stranded Total RNA Library Prep Kit
with Ribo-Zero Gold and bar-coded with individual tags following the manufacturer’s instructions (Illumina). Libraries were prepared
on an Agilent Bravo Automated Liquid Handling System. Quality control was performed at every step, and the libraries were
quantified using a TapeStation system.
Total RNA Sequencing
Indexed RNA-seq libraries were sequenced using the HiSeq4000 platform to generate a minimum of 120 million paired end reads
(75 base pairs) per library with a target of greater than 90% mapped reads. The sequence data were demultiplexed and converted
to FASTQ files, and adaptor and low-quality sequences were quantified/trimmed. Samples were then assessed for quality by
mapping reads to the hg38 reference genome, estimating the total number of reads that mapped, assessing the amount of RNA
that mapped to coding regions, the amount of rRNA in the sample, the number of genes expressed, and the relative expression
of housekeeping genes. Samples that passed the quality criteria were then clustered with other expression data from similar and
distinct tumor types to confirm expected expression patterns, including pathological status (i.e., normal adjacent versus tumor
tissue) and tissue-origin specificity. FASTQ files of all reads were then uploaded to the GDC repository.
Proteomic Sample Preparation and Data Acquisition
Sample Processing for Protein Extraction and Tryptic Digestion
All samples for the current study were prospectively collected as described above and processed for mass spectrometric (MS)
analysis at the PCC. Tissue lysis and downstream sample preparation for global proteomic and phosphoproteomic analysis were
carried out as previously described (Mertins et al., 2018). Approximately 25-120 mg of each cryopulverized renal tumor tissues or
NATs were homogenized separately in an appropriate volume of lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris, pH 8.0, 1 mM
EDTA, 2 mg/mL aprotinin, 10 mg/mL leupeptin, 1 mM PMSF, 10 mMNaF, Phosphatase Inhibitor Cocktail 2 and Phosphatase Inhibitor
Cocktail 3 [1:100 dilution], and 20 mM PUGNAc) by repeated vortexing. Lysates were clarified by centrifugation at 20,000 x g for
10 min at 4C, and protein concentrations determined by BCA assay (Pierce). Lysates were diluted to a final concentration of
8mg/mLwith lysis buffer, and 800 mg of protein was reducedwith 5mMdithiothreitol (DTT) for 1 h at 37C and subsequently alkylated
with 10 mM iodoacetamide for 45 min at RT (room temperature) in the dark. Samples were diluted 1:3 with 50 mM Tris-HCl (pH 8.0)
and subjected to proteolytic digestion with LysC (Wako Chemicals) at 1 mAU:50 mg enzyme-to-substrate ratio for 2 h at RT, followed
by the addition of sequencing-grade modified trypsin (Promega) at a 1:50 enzyme-to-substrate ratio and overnight incubation at RT.
The digested samples were then acidified with 50% trifluoroacetic acid (TFA, Sigma) to a pH value of approximately 2.0. Tryptic
peptides were desalted on reversed-phase C18 SPE columns (Waters) and dried using a Speed-Vac (Thermo Scientific).
TMT Labeling of Peptides
Tandem-mass-tag (TMT) quantitation utilizes reporter ion intensities to determine protein abundance and facilitate quantitative
proteomic analysis (Ross et al., 2004). Previously, CPTAC used two major LC-MS/MS-based methods for quantitative proteomics:
label-free quantification (LFQ) and isobaric tag for relative and absolute quantitation (iTRAQ) for proteogenomic characterization
of colorectal, breast, and ovarian cancers (Mertins et al., 2016; Zhang et al., 2014a, 2016). Inherent benefits of isobaric tag
approaches over LFQ for protein quantitation include decreasing peptide/protein quantification differences attributed to variation
in instrument performance, reducing the number ‘‘missing values,’’ and facilitating integrated measurements of global protein and
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post-transcriptional modifications (PTM) levels (Hogrebe et al., 2018; Thompson et al., 2003). Recent developments in isobaric tag
technology have enabled an increase in the number of independent samples that can be analyzed in parallel, thereby, increasing
throughput and facilitating deeper quantification of respective proteomes (McAlister et al., 2012; Werner et al., 2012). Desalted pep-
tides from each sample were labeled with 10-plex TMT (Tandem Mass Tag) reagents (Thermo Fisher Scientific). Peptides (300 mg)
from each ccRCC and NAT sample were dissolved in 300 mL of 50 mM HEPES, pH 8.5 solution. Five milligrams of TMT reagent
was dissolved in 256 mL of anhydrous acetonitrile, and 123 mL of each TMT reagent was added to the corresponding aliquot of pep-
tides. After 1 h incubation at RT, the reaction was quenched by acidification with 50%TFA to pH < 3. A reference sample was created
by pooling an aliquot from individual ccRCC tumors and NAT samples (90 tumors and 72 NATs, representing 90% of the sample
cohort), labeled with the TMT-131 reagent, and included in all TMT 10-plexes as a pooled reference channel. Two internal quality
control (QC) samples, a single, independently-acquired chromophobe renal cell carcinoma (chRCC) tumor sample and an NCI-7
Cell Line Panel sample (Clark et al., 2018), were prepared and interspersed among all TMT 10-plex sets. 110 ccRCC tumor
and 84 NAT samples with eight chromophobe QC aliquots and five NCI-7 QC aliquots were co-randomized to 23 TMT
10-plex sets. The sample-to-TMT channel mapping is shown in https://cptac-data-portal.georgetown.edu/cptac/documents/
S044_CPTAC_CCRCC_Discovery_Cohort_Specimens_r1_Sept2018.xlsx . Following labeling, peptides were mixed according to
the sample-to-TMT channel mapping, concentrated and desalted on reversed-phase C18 SPE columns (Waters) and dried using
a Speed-Vac (Thermo Scientific).
Peptide Fractionation by Basic Reversed-phase Liquid Chromatography (bRPLC)
To reduce the likelihood of peptides co-isolating and co-fragmenting in these highly complex samples, we employed extensive,
high-resolution fractionation via basic reversed-phase liquid chromatography (bRPLC). Previous reports indicate that this approach
can reduce the incidence of isobaric reporter ion ratio distortion effects, which would impact downstream quantitation (Ow et al.,
2011; Rauniyar and Yates, 2014). The desalted, TMT-labeled samples were reconstituted in 900 mL of 20 mM ammonium formate
(pH 10) and 2% acetonitrile (ACN) and loaded onto a 4.6 mm x 250mmRP Zorbax 300 A Extend-C18 column with 3.5 mm size beads
(Agilent). Peptides were separated at a flow-rate of 1mL/min using an Agilent 1200 Series HPLC instrument via bHPLCwith Solvent A
(2% ACN, 5 mM ammonium formate, pH 10) and a non-linear gradient of Solvent B (90% ACN, 5 mM ammonium formate, pH 10) as
follows: 0% Solvent B (9 min), 6% Solvent B (4 min), 6% to 28.5% Solvent B (50 min), 28.% to 34% Solvent B (5.5 min), 34% to 60%
Solvent B (13 min), and holding at 60% Solvent B for 8.5 min. Collected fractions were concatenated into 24 fractions by combining
four fractions that are 24 fractions apart (i.e., combining fractions #1, #25, #49, and #73; #2, #26, #50, and #74; and so on); a 5%
aliquot of each of the 24 fractions was used for global proteomic analysis, dried in a Speed-Vac, and resuspended in 3% ACN/
0.1% formic acid prior to ESI-LC-MS/MS analysis. The remaining sample was utilized for phosphopeptide enrichment.
Enrichment of Phosphopeptides by Fe-IMAC
The remaining 95% of the sample was further concatenated before being subjected to phosphopeptide enrichment using immobi-
lizedmetal affinity chromatography (IMAC) as previously described (Mertins et al., 2013). In brief, Ni-NTA agarose beadswere used to
prepare Fe3+-NTA agarose beads, and 300 mg of peptides were reconstituted in 80% ACN/0.1% trifluoroacetic acid and incubated
with 10 mL of the Fe3+-IMACbeads for 30min. Sampleswere then centrifuged, and the supernatant containing unbound peptideswas
removed. The beads were washed twice and then transferred onto equilibrated C-18 Stage Tips with 80% ACN/0.1% trifluoroacetic
acid. Tips were rinsed twice with 1% formic acid and eluted from the Fe3+-IMAC beads onto the C-18 Stage Tips with 70 mL of
500 mM dibasic potassium phosphate, pH 7.0 a total of three times. C-18 Stage Tips were then washed twice with 1% formic
acid, followed by elution of the phosphopeptides from the C-18 Stage Tips with 50% ACN/0.1% formic acid twice. Samples were
dried down and resuspended in 3% ACN/0.1% formic acid prior to ESI-LC-MS/MS analysis.
ESI-LC-MS/MS for Global Proteome and Phosphoproteome Analysis
Global proteome and phosphoproteome fractions were analyzed using the same instrumentation and methodology. Peptides
(0.8 mg) were separated on an Easy nLC 1200 UHPLC system (Thermo Scientific) on an in-house packed 20 cm x 75 mm diameter
C18 column (1.9 mm Reprosil-Pur C18-AQ beads (Dr. Maisch GmbH); Picofrit 10 mm opening (New Objective)). The column was
heated to 50Cusing a column heater (Phoenix-ST). The flow ratewas 0.200 ml/minwith 0.1% formic acid and 2%acetonitrile in water
(A) and 0.1% formic acid, 90% acetonitrile (B). The peptides were separated with a 6%–30%B gradient in 84min and analyzed using
the Thermo Fusion Lumos mass spectrometer (Thermo Scientific). Parameters were as follows: MS1: resolution – 60,000, mass
range – 350 to 1800 m/z, RF Lens – 30%, AGC Target 4.0e5, Max IT – 50 ms, charge state include - 2-6, dynamic exclusion –
45 s, top 20 ions selected forMS2;MS2: resolution – 50,000, high-energy collision dissociation activation energy (HCD) – 37, isolation
width (m/z) – 0.7, AGC Target – 2.0e5, Max IT – 105 ms.
ESI-LC-MS/MS for Global Proteome Data-Independent Acquisition Analysis
Unlabeled, digested peptide material from individual tissue samples (ccRCC and NAT) was spiked with index Retention Time (iRT)
peptides (Biognosys) and subjected to data-independent acquisition (DIA) analysis. Peptides (0.8 mg) were separated on an Easy
nLC 1200 UHPLC system (Thermo Scientific) on an in-house packed 20 cm x 75 mmdiameter C18 column (1.9 mmReprosil-Pur C18-
AQ beads (Dr. Maisch GmbH); Picofrit 10 mm opening (New Objective)). The column was heated to 50C using a column heater
(Phoenix-ST). The flow rate was 0.200 ml/min with 0.1% formic acid and 3%acetonitrile in water (A) and 0.1% formic acid, 90%aceto-
nitrile (B). The peptides were separated with a 7%–30% B gradient in 84 mins and analyzed using the Thermo Fusion Lumos mass
spectrometer (Thermo Scientific). The DIA segment consisted of oneMS1 scan (350-1650m/z range, 120K resolution) followed by 30
Cell 179, 964–983.e1–e21, October 31, 2019 e6
MS2 scans (variable m/z range, 30K resolution). Additional parameters were as follows: MS1: RF Lens – 30%, AGC Target 4.0e5, Max
IT – 50 ms, charge state include - 2-6; MS2: isolation width (m/z) – 0.7, AGC Target – 2.0e5, Max IT – 120 ms.
Spectral Library generation for Data-Independent Acquisition Analysis
For spectral library generation, an aliquot (2 mg) of unlabeled, digested peptide material from individual tissue samples (ccRCC and
NAT) was pooled and subjected to bRPLC as previously described. Collected fractions were concatenated into eight fractions by
combining twelve fractions that are eight fractions apart (i.e., combining fractions #1, #9, #17, #25, #33, #41, #49, #57, #65, #73,
#81, and #89; #2, #18, #26, #34, #42, #58, #66, #74, #82, and #90; and so on); dried down in a Speed-Vac, resuspended in 3%
ACN, 0.1% formic acid, and was spiked with index Retention Time (iRT) peptides (Biognosys) prior to ESI-LC-MS/MS analysis.
Parameters were the same as previously described for ESI-LC-MS/MS for Global Proteome and Phosphoproteome Analysis with
a high-energy collision dissociation activation energy (HCD) – 34.
Genomic Data Processing
Harmonized Somatic Variant Calling
Details regarding somatic variant calling performed by the GDC are available at: https://docs.gdc.cancer.gov/Data/
Bioinformatics_Pipelines/DNA_Seq_Variant_Calling_Pipeline/, https://gdc.cancer.gov/about-gdc/variant-calling-gdc. The Univer-
sity of Michigan aligned FASTQ files to the GRCh38 references, including alternate haplotypes. Variant calling was performed using
VarDict (germline & somatic) and Strelka2 (somatic). Variant callers were run with default settings, but custom filters were applied.
Strelka was used to generate the primary somatic call-set. Variants called by Strelka had to be either (FILTER = = ’’PASS’’) or
meet the following threshold criteria: allele frequency in the tumor > 0.05, allele frequency in the normal < 0.01, at least five variant
reads, depth in normal > 50, Somatic Evidence Score (EVS) > 90th percentile of overall EVS distribution. These calls were supple-
mented by variants called confidently (FILTER = = ’’PASS’’ and manual review) by VarDict in genes recurrently mutated in ccRCC:
VHL, PBRM1, BAP1, SETD2, KDM5C, PTEN, MTOR, TP53, PIK3CA, ARID1A, STAG2, KDM6A, KMT2C, KMT2D. This strategy
improved sensitivity in ccRCC-mutated genes without sacrificing the accuracy of variant calls genome wide. Washington University
in St. Louis called somatic variants using four tools: Strelka2, Mutect2, VarScan2.3.8, and Pindel0.2.5. SNVs and indels from the four
tools were then merged with SNVs identified by the University of Michigan and GDC pipelines using the following strategy: SNVs
called by any two callers among Mutect2, VarScan2.3.8, and Strelka2 and indels called by any two callers among MUTECT2,
VarScan2.3.8, Strelka2, and Pindel 0.2.5. For the merged SNVs and indels, we applied a cut-off of 14X and 8X coverage for tumor
and normal respectively. SNVs and indels were filtered using aminimal variant allele frequency (VAF) of 0.05 in tumors and amaximal
VAF of 0.02 in normal tissues. Any SNV within 10 bps of an indel identified in the same tumor sample was filtered.
Structural Variant Analysis
Structural variants (SVs) and indels were called from the whole-genomemapped paired-end sequencing reads byManta (Chen et al.,
2016b) with the default record- and sample-level filters. Record-level filters included a QUAL score < 20; somatic variant quality
score < 30; depth greater than 3x the median chromosome depth near one or both variant breakends; for variants significantly larger
than the paired read fragment size, no paired reads support the alternate allele in any sample). Sample-level filters included a
Genotype Quality < 15. This approach optimizes the analysis of somatic variation in tumor/normal sample pairs. The paired and
split-read evidence was combined during the SV discovery and scoring to improve accuracy but did not require split-reads or
successful breakpoint assemblies to report a variant in cases where there is strong evidence otherwise. Calls were prioritized
with three confidence levels based on whether the read evidence included spanning read pairs (level 1: no spanning read pairs,
only split-reads; level 2: one spanning read pair with or without split-reads; level 3: two or more spanning read pairs with or without
split-reads) (Table S2). We mainly focused on levels 2 and 3 SVs with spanning read pair evidence. We extracted the chr3 translo-
cation events from the SV calls and calculated the prevalence of each chr3 translocation types.
We used an independent structural variant callingmethod LUMPY to validate the translocation events (Layer et al., 2014), selecting
the LUMPY Express mode for automated breakpoint detection by using the default parameters. LUMPY Express expected BWA-
MEM aligned BAM files as input and automatically parsed sample, library, and read group. Before running LUMPY, we extracted
the split and discordant read-pairs based on the whole-genome mapped paired-end sequencing reads of each sample, which
were needed by LUMPY. The VCF output file contained the number of supporting reads for each SV event. For those translocation
events that were also detected in LUMPY supported by spanning reads, we labeled them ‘Yes’ in the Validated_by_LUMPY column
(Table S2) indicating that they were validated.
Methylation Analysis
Raw data from Illumina’s EPIC methylation array were made available by GCCs as IDAT files from the CPTAC consortium. The
methylation analysis was performed using the cross-package workflow ‘‘methylationArrayAnalysis’’ (https://master.bioconductor.
org/packages/release/workflows/html/methylationArrayAnalysis.html) available on Bioconductor. In brief, the raw data files (IDAT
files) were processed to obtain the methylated (M) and unmethylated (U) signal intensities for each locus. The processing step
included an unsupervised functional normalization step that has been previously implemented for Illumina 450K methylation arrays
(Fortin et al., 2014). A detection p value was also calculated for each locus, and this p value captured the quality of detection at the
locus with respect to negative control background probes included in the array. Loci having common SNPs (with MAF > 0.01), as per
dbSNP build 132 through 147 via snp132 through snp147 common tracks at the UCSCBrowser, were removed from further analysis.
Beta values were calculated as M/(M+U), which is equal to the fraction methylated at each locus. Beta values of loci with detection
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p value > 0.01 were assigned NA in the output file. All loci were annotated with the annotation information file ‘MethylationEPIC_
v-1-0_B2.csv’ from the zip archive ‘infinium-methylationepic-v1-0-b2-manifest-file-csv.zip’ (https://www.illumina.com) through
the Bioconductor IlluminaHumanMethylationEPICanno.ilm10b2.hg19 package.
Classification of Samples with CpG Island Methylator Phenotype (CIMP)
To classify the tumor samples into CpG island methylator phenotypes (CIMP+ and CIMP-), we performed hierarchical clustering of
the methylation data using CpG probes previously established to distinguish these epigenetic states in ccRCC (Arai et al., 2012). The
parameters used for the hierarchical clustering were ‘‘Euclidean’’ for distance, ‘‘complete’’ for method, and ‘‘none’’ for scale. The
resulting two clusters were verified using the histopathological stage data and well-known gene methylation markers (Shenoy
et al., 2015). The CIMP+ group was enriched with late-stage tumors and the CIMP+/ differential marker genes were recapitulated
based on our classification (Figure S1H; Table S2).
Copy-Number Analysis
Copy-number analysis was performed jointly leveraging both whole-genome sequencing (WGS) and whole-exome sequencing data
of the tumor and germline DNA, using CNVEX (https://github.com/mctp/cnvex). CNVEX uses whole-genome aligned reads to esti-
mate coverage within fixed genomic intervals and whole-genome and whole-exome variant calls to compute B-allele frequencies
(BAFs) at variable positions (we used VarDict germline calls). Coverages were computed in 10kb bins, and the resulting log coverage
ratios between tumor and normal samples were adjusted for GC bias using weighted LOESS smoothing across mappable and non-
blacklisted genomic intervals within the GC range 0.3-0.7, with a span of 0.5 (the target and configuration files are provided with
CNVEX). The adjusted log coverage-ratios (LR) and BAFs were jointly segmented by a custom algorithm based on Circular Binary
Segmentation (CBS). Alternative probabilistic algorithms were implemented in CNVEX, including algorithms based on recursive
binary segmentation (RBS) (Gey and Lebarbier, 2008), and dynamic programming (Bellman, 1961), as implemented in the R-package
jointseg (Pierre-Jean et al., 2015). For theCBS-based algorithm, first LR andmirrored BAFwere independently segmented usingCBS
(parameters alpha = 0.01, trim = 0.025) and all candidate breakpoints collected. The resulting segmentation track was iteratively
‘‘pruned’’ by merging segments that had similar LR, BAFs, and short lengths. For the RBS- and DP-based algorithms, joint-break-
points were ‘‘pruned’’ using a statistical model selection method (Lebarbier, 2005). For the final set of CNV segments, we chose the
CBS-based results as they did not require specifying a prior number of expected segments (K) per chromosome arm, were robust to
unequal variances between the LR and BAF tracks, and provided empirically the best fit to the underlying data. The resulting
segmented copy-number profiles were then subject to joint inference of tumor purity and ploidy and absolute copy number states,
implemented in CNVEX, which is most similar to the mathematical formalism of ABSOLUTE (Carter et al., 2012) and PureCN (Riester
et al., 2016). Briefly, the algorithm inputs the observed log-ratios (of 10kb bins) and BAFs of individual SNPs. LRs and BAFs are
assigned to their joint segments and their likelihood is determined given a particular purity, ploidy, absolute segment copy number,
and number of minor alleles. To identify candidate combinations with a high likelihood, we followed a multi-step optimization
procedure that includes grid-search (across purity-ploidy combinations), greedy optimization of absolute copy numbers, and
maximum-likelihood inferences of minor allele counts. Following optimization, CNVEX ranks candidate solutions. Because the
copy-number inference problem can have multiple equally likely solutions, further biological insights are necessary to choose the
most parsimonious result. The solutions have been reviewed by independent analysts following a set of guidelines. Solutions
implying whole-genome duplication must be supported by at least one large segment that cannot be explained by a low-ploidy so-
lution, inferred purity must be consistent with the variant-allele-frequencies of somatic mutations, and large homozygous segments
are not allowed. Clonal loss or LOH of 3p is very likely in ccRCC, whereas near-haploid and very high ploidy solutions are unlikely.
Classification of Samples with Genome instability
To classify the tumor samples into genome instability+ samples and genome stability- samples, we calculated the proportion of
genome altered (PGA), which is defined as the length of all segments that have copy number (as inferred by CNVEX) different
fromC= 2 K= 1; i.e., diploid heterozygous divided by the total length of the genome. The resulting PGA score is a bimodal distribution
with one peak < 25% and the other peak near 100%. We dichotomized the samples into two genome instability categories using a
cutoff of 0.85, which has the local minimal density separating two peaks. The genome instability+ group was enriched with late-stage
tumors and the CIMP+/ differential marker genes were recapitulated based on our classification (Figure 1C; Table S2).
Transcriptomic Data Processing
Transcriptomic data were analyzed as described previously (Robinson et al., 2017), using the Clinical RNA-seq Pipeline (CRISP)
developed at University of Michigan (https://github.com/mcieslik-mctp/crisp-build). Briefly, raw sequencing data were trimmed,
merged using BBMap, and aligned to GRCh38 using STAR. The resulting BAM files were analyzed for expression using feature
counts against a transcriptomic reference based on Gencode 26. The resulting gene-level counts for protein-coding genes were
transformed into FPKMs using edgeR.
Proteomic Data Processing
Protein database searching and quantification of global and phosphoproteomic data
Raw mass spectrometry files were converted into open mzML format using the msconvert utility of the Proteowizard software suite.
MS/MS spectra were searched using the MSFragger database search tool (Kong et al., 2017) against a CPTAC harmonized RefSeq
protein sequence database appended with an equal number of decoy sequences. For the analysis of whole proteome data, MS/MS
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spectra were searched using a precursor-ion mass tolerance of 20 ppm, fragment mass tolerance of 20 ppm, and allowing C12/C13
isotope errors (1/0/1/2/3). Cysteine carbamidomethylation (+57.0215) and lysine TMT labeling (+229.1629) were specified as fixed
modifications, and methionine oxidation (+15.9949), N-terminal protein acetylation (+42.0106), and TMT labeling of peptide N termi-
nus and serine residues were specified as variable modifications. The search was restricted to fully tryptic peptides, allowing up to
two missed cleavage sites. For the analysis of phosphopeptide enriched data, the set of variable modifications also included
phosphorylation (+79.9663) of serine, threonine, and tyrosine residues.
The search results were further processed using the Philosopher pipeline (https://github.com/Nesvilab/philosopher). Whole pro-
teome and phosphopeptide-enriched datasets were processed separately but using the same pipeline steps, except when noted.
First, MSFragger output files (in pepXML format) were processed using PeptideProphet (Keller et al., 2002) (with the high–mass
accuracy binning and semi-parametric mixture modeling options) to compute the posterior probability of correct identification for
each peptide to spectrummatch (PSM). In the case of the phosphopeptide-enriched dataset, PeptideProphet files were additionally
processed using PTMProphet (Deutsch et al., 2015) to localize the phosphorylation sites. The resulting pepXML files from
PeptideProphet (or PTMProphet) from all 23 TMT 10-plex experiments were then processed together to assemble peptides into pro-
teins (protein inference) and to create a combined file (in protXML format) of high confidence protein groups. Corresponding peptides
were assigned to each group. The combined protXML file and the individual PSM lists for each TMT 10-plex were further processed
using Philosopher filter command as follows. Each peptide was assigned either as a unique peptide to a particular protein group or
assigned as a razor peptide to a single protein group that had the most peptide evidence. The protein groups assembled by
ProteinProphet (Nesvizhskii et al., 2003) were filtered to 1% protein-level False Discovery Rate (FDR) using the chosen FDR
target-decoy strategy and the best peptide approach (allowing both unique and razor peptides) and applying the picked FDR strategy
(Savitski et al., 2015). In each TMT 10-plex, the PSM lists were filtered using a stringent, sequential FDR strategy, retaining only those
PSMs with PeptideProphet probability of 0.9 or higher (which in these data corresponded to less than 1% PSM-level FDR) and map-
ped to proteins that also passed the global 1% protein-level FDR filter. For each PSM that passed these filters, MS1 intensity of the
corresponding precursor-ion was extracted using the Philosopher label-free quantification module based on the moFF method (Ar-
gentini et al., 2016) (using 10 p.p.mmass tolerance and 0.4 min retention time window for extracted ion chromatogram peak tracing).
In addition, for all PSMs corresponding to a TMT-labeled peptide, ten TMT reporter ion intensities were extracted from the MS/MS
scans (using 0.002 Dawindow) and the precursor ion purity scoreswere calculated using the intensity of the sequenced precursor ion
and that of other interfering ions observed in MS1 data (within a 0.7 Da isolation window). All supporting information for each PSM,
including the accession numbers and names of the protein/gene selected based on the protein inference approachwith razor peptide
assignment and quantification information (MS1 precursor-ion intensity and the TMT reporter ion intensities) was summarized in the
output PSM.tsv files, one file for each TMT 10-plex experiment. The PSM.tsv files were further processed using TMT-Integrator
(https://github.com/Nesvilab/TMT-Integrator) to generate summary reports at the gene and protein level and, for phosphopeptide
enriched data, also at the peptide and modification site levels. In the quantitation step, TMT-Integrator used as input the PSM tables
generated by the Philosopher pipeline as described above and created integrated reports with quantification across all samples at
each level. First, PSM from PSM.tsv files were filtered to remove all entries that did not pass at least one of the quality filters, such as
PSMs with (a) no TMT label; (b) missing quantification in the Reference sample; (c) precursor-ion purity less than 50%; (d) summed
reporter ion intensity (across all ten channels) in the lower 5%percentile of all PSMs in the corresponding PSM.tsv file (2.5% for phos-
phopeptide enriched data); (e) peptides without phosphorylation (for phosphopeptide enriched data). In the case of redundant PSMs
(i.e., multiple PSMs in the same MS run sample corresponding the same peptide ion), only the single PSM with the highest summed
TMT intensity was retained for subsequent analysis. Both unique and razor peptides were used for quantification, while PSMs map-
ping to common external contaminant proteins (that were included in the searched protein sequence database) were excluded. Next,
in each TMT 10-plex experiment, for each PSM the intensity in each TMT channel was log2 transformed, and the reference channel
intensity (pooled reference sample) was subtracted from that for the other nine channels (samples), thus converting the data into
log2-based ratio to the reference scale (referred to as ‘ratios’ below). After the ratio-to-reference conversion, the PSMswere grouped
on the basis of a predefined level (gene, protein, and also peptide and site-level for phosphopeptide enriched data; see below for
details). At each level, and in each sample, the interquartile range (IQR) algorithm was applied to remove the outliers in the
corresponding PSM group. The first quantile (Q1), the third quantile (Q3), and the interquartile range (IQR, i.e., Q3-Q1) of the sample
ratios were calculated, and the PSMs with ratios outside of the boundaries of Q1-1.5*IQR and Q3+1.5*IQR were excluded. Then, the
median was calculated from the remaining ratios to represent the ratio for each sample, at every level. In the next step, the ratios were
normalized using the median absolute deviation (MAD). Briefly, independently at each level of data summarization (gene, protein,
peptide, or site), given the p by n table of ratios for entry j in sample i, Rij, the median ratio Mi = median(Rij, j = 1,.,p), and the global
median across all n samples,M0 =median(Mi, i = 1,.,n), were calculated. The ratios in each sample weremedian centered, R
C
ij = Rij –
Mi. The median absolute deviation of centered values in each sample, MADi = median(abs(R
C
ij), j = 1.p) was calculated along with
the global absolute deviation, MAD0 = median(MADi, i = 1,.,n). All ratios were then scaled to derive the final normalized measures:
RNij = (R
C
ij/ MADi) 3MAD0 + M0. As a final step, the normalized ratios were converted back to the absolute intensity scale using the
estimated intensity of each entry (at each level, gene/protein/peptide/site) in the Reference sample. The Reference Intensity of entry i
measured in TMT 10-plex k (k = 1,.,q), REFik, was estimated using the weighted sum of the MS1 intensities of the top three most
intense peptide ions (Ning et al., 2012) quantified for that entry in the TMT 10-plex k. The weighting factor for each PSMwas taken as
the proportion of the reference channel TMT intensity to the total summed TMT channel intensity. The overall Reference Intensity for
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entry i was then computed as REFi = Mean(REFik, k = 1,.,q). In doing so, the missing intensity values (i.e., no identified and/or
quantified PSMs in a particular TMT 10-plex experiment) were imputed with a global minimum intensity value. The final abundance
(intensity) of entry i in sample j (log2 transformed) was computed as Aij = R
N
ij + log2(REFi). The ratio and intensity tables described
above were calculated separately for each level (gene and protein for whole proteome, and also peptide and site-level for phospho-
peptide enriched data). PSMs were grouped as follows. At the gene level, all PSMs were grouped based on the gene symbol of the
corresponding protein to which they were assigned as either unique or razor peptides. In the protein tables, identified proteins that
mapped to the same gene were kept as separate entries. To generate peptide-level and site-level tables, additional post-processing
was applied to generate all non-conflicting phosphosite configurations using a strategy similar to that described in Huang et al.
(2017). In doing so, confidently localized sites were defined as sites with PTMProphet localization probability of 0.9 or higher. The
same peptide sequences but with different site configurations, i.e., different site localization configurations or peptides with unlocal-
ized sites, were retained as separate entries in the site-level tables. In the peptide-level tables, different site-level configurations were
combined into a single peptide-level index, grouping PSMs with all site configurations together if they corresponded to the same
peptide sequence. The tutorial describing all steps of the analysis, including specific input parameter files, command-line option,
and all software tools necessary to replicate the results are available at https://github.com/Nesvilab.
Creation of a Patient-Specific Protein Sequence Database
The proteogenomic database tool pyQUILTS (Ruggles et al., 2016), available at http://quilts.fenyolab.org, was used to incorporate
the germline and somatic SNVs and RNA-seq-predicted junctions into a searchable protein database. The human RefSeq protein
database (downloaded 2018/06/29) was used as a reference for the hg38 proteome and genome.
Variant Peptide Identification and Neoantigen Prediction
NeoFlow (https://github.com/bzhanglab/neoflow) was used for neoantigen prediction. Specifically, Optitype (Szolek et al., 2014) was
used to identify human leukocyte antigens (HLA) in the WES data. netMHCpan (Jurtz et al., 2017) was then used to predict HLA
peptide binding affinity for somatic mutation–derived variant peptides with a length between 8-11 amino acids. The cutoff of IC50
binding affinity was set to 150 nM. HLA peptides with binding affinity higher than 150 nM were removed. Variant identification
was also performed at the mRNA and protein levels using RNA-seq data and MS/MS data, respectively. To identify variant peptides,
we used a customized protein sequence database approach (Wang et al., 2012). Two different workflows were used. In the first
workflow, we derived customized protein sequence databases from matched WES data and performed database searching using
the customized databases for individual TMT experiments. We built a customized database for each TMT experiment based on
somatic variants from WES data. Customprodbj (https://github.com/bzhanglab/customprodbj) was used to construct customized
databases. MS-GF+ was used to identify variant peptides for all global proteome and phosphorylation data. Results from MS-
GF+ were filtered with 1% FDR at PSM level. Remaining variant peptides were further filtered using PepQuery (http://www.
pepquery.org) (Wen et al., 2019) with the p value cutoff % 0.01. Variant peptide spectra were annotated using PDV (http://www.
zhang-lab.org/) (Li et al., 2019). In the second workflow, the RefSeq-based protein database used in the main analysis was trypsin
digested in silico allowing up to one missed cleavage and treating N-terminal methionine excision as a variable modification to
produce two sets of N-terminal peptides (methionine excised andmethionine retained). One additional missed cleavagewas retained
for peptides containing KP and RP amino acids. Isoleucine and leucine occurrences were set to leucine as they are indistinguishable
during peptide sequencing. QUILT-derived, patient-specific protein FASTA files corresponding to all samples within a given TMT-
plex were combined. From these files, a set of unique peptides was generated from each protein, and any of these peptides that
occurred within the RefSeq database were removed. The result of this process was a protein FASTA file, in which every
peptide present within the combined personalized QUILT FASTA that was not found within the RefSeq database was retained for
searching. The new customized databases were used to search each corresponding dataset against spectra previously classified
as having a PeptideProphet score lower than 0.5. The new database searches were carried out using the MSFragger methodology
described previously (Kong et al., 2017). Resulting PSMs were filtered, keeping only charge states 2, 3 and 4 and PSMs with delta
mass between > -.05 and 2.5. After scoring all identifications with FDRs, the best PSM from each experiment was selected, gener-
ating quantitation tables of raw abundance and ratio to common reference. In global and phosphorylation-enriched datasets, post
processing was completed to annotate misidentified novel peptides that are contained within UniProt Swiss-Prot (ret. 22 June 2019)
and to identify the patients from which each novel peptide was derived. In the phosphorylation-enriched dataset, a column (called
isMatch) was added to check whether mutation sites overlap with novel peptide phosphorylation sites. The somatic variant peptides
identified by either of the two workflows were used for downstream analysis.
Protein database searching and quantification of global data independent acquisition data
Raw mass spectrometry files from DIA (n = 194) and DDA (n = 8) platforms were processed using the DIA-Umpire (Tsou et al., 2015)
based pipeline to generate a combined spectral library that integrated DDA and DIA search results. In brief, DIA data were first
processed using DIA-Umpire to generate deconvoluted (pseudo-MS/MS) spectra. DDA and pseudo-MS/MS DIA spectra were
then searched using theMSFragger (Kong et al., 2017) search engine against the sameCPTACharmonized RefSeq protein sequence
database as for TMT data analysis (with an addition of the sequences of iRT peptides). The search was completed using tryptic
peptides only, allowing up to two missed cleavages, allowing methionine oxidation and protein N-terminal acetylation as variable
modifications, and cysteine carbamylation as a fixed modification. The search results were further processed using the Philosopher
pipeline, including PeptideProphet and iProphet (run using the same settings as for TMT data as described above). Retention times of
peptide identifications from all DIA and DDA runs were aligned to a single reference DIA run using high quality peptide identifications.
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ProteinProphet was run using all iProphet pepXML files (i.e., from all DIA and DDA runs) to generate a single combined protXML file,
and the protein list was filtered to 1%protein-level FDR. PSMs identified in each individual data subset (DDA or DIA) were then filtered
using the Philosopher filter utility to 1% peptide ion-level FDR separately in each subset. Only those PSMs that mapped to proteins in
the 1%protein-level FDR filtered combinedDDAplusDIA protein list were retained. These filtered PSMs,with aligned retention times,
were used to generate two spectral libraries using SpectraST, one for DIA and one for DDA data subsets. The retention times were
further transformed to the indexed retention time (iRT) scale using standard peptides spiked into the samples. The consensusMS/MS
spectra were generated for each peptide ion, and the spectral libraries were refined to contain only selected peptide fragments using
the spectrast2tsv script from themsproteomicstools resource (https://github.com/msproteomicstools), requiring aminimum of three
and a maximum of six fragments per spectrum, fragment m/z values between 250 and 2000 Da only, and b and y ion types only, but
allowing neutral losses of water or ammonia. The resulting DIA andDDA spectral libraries were combined.When the same peptide ion
was present in both libraries, the DIA spectrum was selected for the combined library. The combined library was then converted to
Spectronaut (Biognosys) format for subsequent targeted re-extraction of quantification information. The combined spectrum library
was loaded into Spectronaut, and targeted quantification was performed using default settings. For protein quantification, all abun-
dances were calculated as the area under the extracted ion chromatogram (XIC) of all selected fragments that passed filtering. The
data were filtered using the global protein-level FDR value of 1%, and proteins were quantified in each individual DIA run using pep-
tides that passed the run-specific peptide ion q-value of 0.01. Protein abundances for select candidates (PECAM1, VEGFA, PKM,
HLA-C, C5, HLA-A, PGM1, HLA-B, POSTN, STAT1) were extracted and reported in Table S7. DIA expressionmatrix of select proteins
(ccRCC-DIA_selected_proteins.csv) is available at https://cptac-data-portal.georgetown.edu/cptac/s/S050
Preprocessing of ccRCC proteomics data
Global protein and phosphosite abundances from 194 samples were measured in 23 TMT-10plexes in this experiment, which iden-
tified 11,355 unique genes in global protein abundance along with 100,730 phosphosites. There were 18.4% data missing in global
protein abundance with 7,150 genes completely observed. In the phosphoproteomic analyses, 67.5% of data was missing in phos-
phosite abundance, with 5,584 phosphosites from 2,443 genes completely observed. Before performing any downstream analysis,
we applied batch correction on global and phosphoproteome abundance to remove the technical difference between different TMT
10-plexes. An R tool, ComBat, with tumor/normal status adjustment was applied to remove batch effects (Johnson et al., 2007). To
impute missing values, we used DreamAI (https://github.com/WangLab-MSSM/DreamAI), an ensemble algorithm developed during
the NCI-CPTAC Dream Proteomics Imputation Challenge (https://www.synapse.org/#!Synapse:syn8228304/wiki/413428). Only
those phosphosites and proteins with a missing rate less than 50% were imputed. After imputation, the number of phosphosites
deemed valid for downstream analyses was boosted to 26,814 (from 5,571 genes).
Sample labeling check of ccRCC dataset
Integrating multiple layers of omics data enhances our understanding of complex molecular mechanisms in biological systems.
However, unintended errors in annotations and sample mislabeling often occur when generating and managing large-scale data
(Alyass et al., 2015). Since integrative analysis based on erroneous data could lead to inaccurate scientific conclusions, a sam-
ple-labeling check is a critical QC step before integration. In this study, we performed a systematic QC procedure to confirm that
all annotations in clinical information and sample names were consistent. We checked tissue annotations (tumor or normal), gender
annotations (male or female), and sample matching among RNA-seq, proteomics and phosphorylation data.
1. Tissue Annotation. We performed PCA independently in RNA-seq, proteomics and phosphorylation data. As expected, normal
and tumor tissues were well separated without exception, suggesting that tissue information is consistent with given
annotation.
2. Gender Annotation. Expression of marker genes in X and Y chromosomes can help to infer gender of the samples from which
they are analyzed (Staedtler et al., 2013). After combining all normal and tumor RNA-seq samples, male- and female-annotated
samples were compared on a t test. Two Y chromosome genes (RPS4Y1 andDDX3Y) showed the strongest separation (t test p
values = 6.13 10140 and 4.43 10136 respectively). When using the expression of these two genes, genders agreed between
annotation and expression in all samples. When a similar approach was applied to proteomics and phosphorylation data, the
signal was less clear than in RNA-seq data. Hence, it proved difficult to check gender consistency using proteomics and phos-
phorylation data.
3. Sample Alignment. Although we assessed the accuracy of tissues and gender information, samplemislabeling could still occur
by swapping, shifting, or duplicating two samples from the same tissue or genders. Therefore, it is necessary to confirm that
complementary samples used in RNA-seq, proteomics, and phosphorylation analyses are from the same individuals. We
applied a pairwise alignment procedure developed by us previously (Yoo et al., 2014) using all samples that compared global
proteomics and phosphoproteomics, RNA-seq and global proteomics, and RNA-seq and phosphoproteomics. First, the top
500 cis genes were identified based on the correlation coefficient for each of proteomics-phosphorylation, RNA-seq-prote-
omics, and RNA-seq-phosphorylation pair. Then the values of the 500 genes were rank-transformed to obtain a sample-
wise similarity score. If a sample matches between two types of data, its sample similarity score should be higher than the
score when compared to other cases, which have null distribution with mean 0. Using this approach, we confirmed that all
110 tumor and 84 normal tissues were perfectly matched between global proteomic and phosphoproteomic data. All tumor
samples in RNA-seq were well matched with their corresponding global proteomic and phosphoproteomic data except for
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one normal sample, CPT0012090003, whose self-similarity score did not differ from scores corresponding to other samples
(Figure S1A; Table S1). Indeed, the RNA expression of this sample did not match its proteomic profile (both global and
phosphoprotein abundance). While this error could arise from either RNA-seq or global-proteomic/phosphorylation data since
global proteomic and phosphorylation data for this sample were well aligned. This sample was removed from all further
downstream analysis as the error-source remained unresolved.
CNV Integrated Analysis
Genomic determination of 103 ccRCC versus 7 non-ccRCC samples from 110 pathologically defined ccRCC tumors
Outlier samples identified PCA of by RNA-seq data using Omics Explorer (Qlucore, Lund, Sweden) also exhibited low expression of
ccRCC biomarkers such as ANGPTL4, CA9, and NDUFA4L2, among others and were subject to further critical evaluation for
genomic aberrations (copy number variations (CNVs) and mutations) (Figures S1B–S1D). Samples C3N-00492 and C3N-00175
showed one copy loss of chromosomes 1, 2, 6, 10, 13 and 17 along with TP53 mutations and contained high expression of several
biomarkers (such as FOXI1, RHCG) (Lindgren et al., 2017) that are characteristic of chromophobe RCC (chRCC). In addition, samples
C3N-00832 and C3N-00313 containedPTENmutations, and the latter also showed outlier expression of the papillary RCC biomarker
VSTM2A (Wang et al., 2018a), along with gain of chr7, and PIK3R1 mutation and were thus categorized as likely papillary RCCs.
Sample C3L-00359 contained bi-allelic loss of TSC1 along with histologic features of eosinophilic solid cystic RCC (ESC-RCC)
(Mehra et al., 2018), while C3N-01180 had a SFPQ-TFE3 gene fusion, a hallmark of translocation RCC. Finally, C3N-00435 contained
3p loss with a PIK3CA hotspot mutation. These seven samples were therefore annotated as non-ccRCC samples and excluded from
the ccRCC cohort in all downstream analyses (Table S1).
Detection of Chromosomal Arm-Level Aberration
GISTIC2 (Mermel et al., 2011) was used to process the segment-level CNV log ratios and define chromosome arm-level gain/loss
events for 3p, 5q, 7p, 9p, and 14q, using the default threshold setting (i.e., -ta and -td were both set to 0.1). From the GISTC2
arm-level outputs, we defined the positive and negative values as arm gain and loss events, respectively. Since GISTIC2 by design
ignores arm-level CNVs, we next identified arm-level recurrence of gains/losses using an alternate approach. For each chromosome
arm, we calculated the average (weighted) maximum-likelihood copy number (clonal or subclonal) relative to 2 (diploid). Similarly, for
each chromosome arm, we calculated the proportion of the arm that shows LOH, including copy-neutral LOH. Following threshold-
ing, (for CN gain (> 0.5) or loss (<0.5)) these two proportions were used to estimate population-level recurrence of arm-level losses/
gains and LOH, respectively. For chromosome 3p, only the loss (< 0.5) was investigated for LOH (defined as > 0.5). The detailed
annotation of all chromosome arm events is provided (Table S2).
Heatmap Web Server
Wedeveloped an online application that allows researchers to query the dataset for genes of interest, rendering a downloadable table
and corresponding heatmap visualization of the select data. The underlying data consist of quantitative information on copy number
alteration, mutation, methylation, RNA-seq gene expression, protein expression, and phosphosite expression for 22,867 genes
across 110 samples. Data tracks for each gene are labeled as: ‘‘Mut’’–mutation data (‘‘Yes’’ is any types of mutation, ‘‘No’’ is no
mutation), ‘‘Methy’’–beta value of CpG island in the promoter region of the gene (standardized), ‘‘CNV (lr)’’–the log ratio of copy
number variation, ‘‘CNV (baf)’’–the b-allele frequency of the copy number variation (standardized), ‘‘mRNA’’–gene expression levels
(standardized), ‘‘Protein’’–gene-level protein abundance (standardized), and ‘‘Phospho’’–gene-level phosphoprotein abundance
(standardized). Genomic and clinical annotation data are displayed on the top and bottom of the visualization. Tracks on the top
include genomically confirmed ccRCC and non-ccRCC, 3p copy number variation, and an immune grouping for each sample.
Bottom-placed tracks visualize CNV data for chromosomes 5q, 7p, 9p, and 14q, t(3;2) and t(3;5) chromosome translocations,
CIMP status, and genomic instability status, as well as grade, stage, and gender information. The application can be accessed at
http://ccrcc.cptac-data-view.org. This is an entirely web-based application, and users do not need to download any software outside
of a web browser to visualize and access the data. Users begin by entering official symbols for up to thirty genes into a text field. For
convenience, the input gene list may be separated by tabs, commas, semicolons, single spaces, or line breaks. All gene symbols
found in the underlying dataset will be used to generate an Excel file (.xls) and corresponding heatmap visualization. The raw data
and graphic visualization (.png) can be downloaded to a local computer for further exploration or for use in publication. The applica-
tion can also be used for interactive visual exploration of the data. Users may click any data point on the interactive heatmap to view
the underlying values, including the sample identifier, data type, and value. By clicking a link next to the sample identifier, users can
view direct links to the histological images corresponding to the sample, organized by tissue location. When available, the user can
click gene symbols on the heatmap to view summary descriptions from the NCBI. Users can sort the entire heatmap by a single data
track, in ascending or descending order. The sorted visualization can then be downloaded with a button. This functionality enables
users to explore dynamically the relationships and patterns among different tracks.
Downstream Analysis of Chromosome Arm 3p translocation
This cohort featured frequent chromosome 3p arm translocation (e.g., to chromosome 5q and results in 3p loss and 5q gain) (Fig-
ure 1B). An association analysis of chromosome 3p arm translocation events was performed with each of the 9,190 protein abun-
dances (with missing rate < 50%) across 110 ccRCC tumor samples to identify the proteomic functional impacts of the translocation
events. Specifically, three types of translocation categories, Chr3-Chr2, Chr3-Chr5, andChr3-other, were simultaneously considered
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in the regression models, and an ANOVA test was applied to assess whether any translocation was associated with the protein
abundances in the tumors. Age, gender, ischemic time, OCT status and tumor purity were adjusted as covariates. The most
significant protein was SETD2 (p = 8E – 6; FDR < 0.05). Post-ANOVA assessment of each event indicated that Chr3-Chr2 transloca-
tion was significantly associated with decreased abundance in SETD protein abundance (Figure S1F), which is consistent with the
high mutation rate observed in Chr3-Chr2 group (Figure S1E).
iProFun-Based Cis Association Analysis
The integrative analysis tool, iProFun (Song et al., 2019), was used to identify functional molecular quantitative traits perturbed by
DNA-level variations (https://github.com/WangLab-MSSM/iProFun). Compared to analyzing each molecular trait separately, iPro-
Fun models multi-omic data jointly, thereby enhancing the power for detecting significant cis-associations shared across different
omics data types and achieves better accuracy in inferring cis-associations unique to certain types of molecular traits. Specifically,
we considered three functional molecular quantitative traits (mRNA expression levels, global protein abundances, and phosphopep-
tide abundances) for their associations with four DNA-level variations (copy number alterations measured by log ratios, copy number
alterations measured by b-allele frequency, DNA methylations and somatic mutations).
Data and preprocessing:
We analyzed data from 110 tumors in the CPTAC cohort. mRNA expression levels measured with RNA-seq were available for 19,293
genes (https://cptac-data-portal.georgetown.edu/cptac/s/S050; RNA_rpkm_tumor_normal.tsv), while global protein abundance mea-
surements were available for 11,355 genes (https://cptac-data-portal.georgetown.edu/cptac/s/S050; CPTAC3_CCRCC_Whole_
abundance_gene_protNorm = 2_CB.tsv) and the phosphopeptide abundances were available for 42,893 peptides (https://
cptac-data-portal.georgetown.edu/cptac/s/S050; CPTAC3_CCRCC_Phospho_abundance_phosphopeptide_protNorm%3D2_CB_
1211.tsv) from 8,502 genes. The log ratios and b-allele frequencies of copy number alterations were obtained from WGS and WES
data using a segmentation method for 19,285 and 19,293 genes, respectively. The DNA methylation levels (beta values) averaging
the CpG islands located in the upstream and nearby transition starting site (TSS) regions, including 5UTR, first exon, and upstream
TSS were available for 15,885 genes. Somatic mutations were called using WES (see SNV calling section above). All data types
were preprocessed to eliminate potential issues such as batch effects, missing data, and major unmeasured confounding effects.
All seven types of data were filtered with a missing rate > 50%. mRNA expression levels and global protein and phosphoprotein abun-
danceswere also normalized to a standard normal distribution. Somatic mutations with > 5% frequency were considered in iProFun for
their functional consequences onmolecular quantitative traits (QTs). To account for potential confounding factors, we considered age,
gender and tumor purity. Tumor purity was determined from RNA-seq data using ESTIMATE (Yoshihara et al., 2013).
iProFun procedure:
The iProFun procedure was applied to 4,009 genes measured across all six data types (mRNA, global protein, phosphoprotein,
CNA – lr, CNA – baf, DNA methylation) for their cis regulatory patterns in tumors. Thirteen genes with frequent somatic mutations
(mutation rate > 5%) were also considered for their effects on cis molecular QTs. Specifically, for the remaining 3986 genes, we
considered the following three regressions:
mRNA CNV (lr) + CNV (baf) + methy + covariates,
global CNV (lr) + CNV (baf) + methy + covariates, and
phosphor CNV (lr) + CNV (baf) + methy + covariates.
For the thirteen genes with frequent somatic mutations we considered the following three regressions:
mRNA CNV (lr) + CNV (baf) +methy + mutation + covariates,
global CNV (lr) + CNV (baf) +methy + mutation + covariates, and
phosphor CNV (lr) + CNV (baf) +methy + mutation + covariates,
The association summary statistics of CNV (lr), CNV (baf), and methy from two sets of regression frameworks were combined and
applied to iProFun to call the posterior probability of belonging to each of the eight possible configurations (‘‘None,’’ ‘‘mRNA only,’’
‘‘global only,’’ ‘‘phosphor only,’’ ‘‘mRNA & global,’’ ‘‘mRNA & phosphor,’’ ‘‘global & phosphor,’’ and ‘‘all three’’) (Figure S2A), to
estimate the variation of molecular QTs explained by each DNA variations (R̂2), and to determine significance associations.
Table S3 and Figure S2B present the significant genes that pass three criteria: (1) satisfying the biologic filtering procedure, (2) pos-
terior probabilities > 75%, and (3) empirical false discovery rate (eFDR) < 5%. Specifically, we posed the biological filtering criterion
for CNV and DNA methylations. Only CNV (lr) that were positively associated with all the types of molecular QTs, DNA methylations
that were negatively associated with all types of molecular QTs, and CNVs (baf) with associations of consistent direction (either pos-
itive or negative) with all types of molecular QTs were considered for significance calling. A significance was then called only if the
posterior probability > 75% of a predictor being associated with a molecular QT was greater than 75%, by summing over all config-
urations that are consistent with the association of interest. For example, the posterior probability of a DNA methylation being
associated with mRNA expression levels was obtained by summing up the posterior probabilities in the following four association
patterns – ‘‘mRNA only,’’ ‘‘mRNA & global,’’ ‘‘mRNA & phosphor,’’ and ‘‘all three,’’ all of which were consistent with the association
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of DNA methylation with mRNA expression. Lastly, we calculated empirical FDR (eFDR) via 100 permutations per molecular QTs by
shuffling the label of the molecular QTs and requesting eFDR < 5% by selecting a minimal cutoff value of alpha such that 75% <
alpha < 100%. The eFDR is calculated by:
eFDR= ðAveraged number of genes with posterior probabilities>alpha in permuted dataÞ=
ðAveraged number of genes with posterior probabilities>alpha in original dataÞ:
Among all the geneswhose phosphoproteins were significantly associatedwith tumor versus normal andwith tumor grade, CNV, and
methylation with cascade effects, i.e., demonstration of significant association with all of the three traits (mRNA levels, protein and
phosphopeptide abundances) were plotted in Figure 2A. Table S3 catalogs R̂2 range (0, 1) by providing the percentage of adjusted
variances explained by each type of DNA alterations. These R̂2 were obtained by contrasting multiple regression R̂2 values between
the full model and models without the predictor of interest. For example, to calculate R̂2 of DNA methylation of a gene with a low
mutation rate on its cismRNA, the R̂2_full value is generated frommodel mRNACNV (lr) + CNV (baf) + methy + covariates, whereas
the R̂2_reduced value is from model mRNA CNV (lr) + CNV (baf) + covariates. The difference, R̂2_diff is calculated as R̂2_full –
R̂2_reduced and represents R̂2 of mRNA explained by DNA methylation in this gene. For the additional thirteen somatic mutations,
posterior probabilities could not be called robustly using iProFun, as alternative densities used in iProFun cannot be inferred
accurately using only thirteen observations. We only required eFDR < 5% and consistent direction in association with all types of
molecular QTs to call significance. The R̂2 can be obtained in the sameway as in other DNA variations. Table S3 presents the iProFun
results based on measured mRNA and protein, without considering phosphoprotein. This exercise begins with a large number of
genes that are measured across mRNA and protein.
Trans Association Analysis
We analyzed ten genomic features to understand their cis and trans associations with multi-omic molecular QTs in 110 cases in this
cohort (Figures 2B and S2D). Specifically, we considered multiple linear regression to evaluate the association between each pair of
genomic feature and molecular trait adjusting for potential confounding factors. The mRNA expression and global protein abun-
dances were considered at gene-level, and the phosphopeptide data were considered at the peptide level. In ccRCC, a total of
19,293 mRNA expression levels, 11,355 global protein abundances and 42,893 peptide-level phosphoprotein abundances were
quantified, respectively. We required a missing rate < 50% for consideration in association analyses, with 17,461 mRNA expression
levels, 9,190 protein abundances and 21,245 phosphopeptide abundances being analyzed. All outcomes were normalized to match
to a standard normal distribution before entering the regression models. We considered five chromosome arm-level genomic
features (3p, 5q, 7p, 9p and 14q) that are most prevalent in the genome, one global methylation feature (CpG Island Methylator
Phenotype (CIMP)), and five key mutations (VHL, PBRM1, BAP1, SETD2, KDM5C) for ccRCC (Table S3). For chromosome arms
3p and 14q, we compared copy loss with copy neutral. For chromosome arm 5q and 7p, we compared amplification with neutral.
In 7p, we excluded four samples with loss from the analysis. CIMP was treated as a categorical variable; CIMP+ and CIMP- were
compared in regression. For five mutations, we grouped all mutation types for power purposes and compared mutation versus
no mutation in the analysis. We adjusted for potential confounding factors that could affect the association between trans genomic
features andmolecular traits in the analyses, including age, gender, OCT embedding, ischemic time, and tumor purity. Ischemic time
was calculated as minutes from the initial clamping to collection and minutes from collection to freezing, if a clamp was used in the
surgery. If no clamp was used in the surgery, the ischemic time was defined as minutes from collection to freezing. We considered
eFDR to call for significance to account for complex unknown gene/gene correlations. Specifically, we first calculated t statistics for
the association between a genomic feature and all genes/peptides of a given data type (e.g., mRNA) via multiple regression, thus
adjusting for confounding factors. We then permuted our sample 100 times by shuffling the sample label of the outcomes to re-calcu-
late the t statistics. For a pre-specified t statistics cut-off value, T, a gene was considered positive if it’s absolute t statistics were
greater than T. Empirical FDR was calculated as noted previously for a pre-specified T value. The smallest T values that allow an
averaged empirical FDR < 10% were used as the final cutoffs, and all genomic feature and molecular trait pairs with absolute t sta-
tistics greater than the cutoff were considered significant associations. The significant trans associations of the selected key features
(3p loss, 5q amplification, 7p amplification, 9p loss, 14q loss, CIMP, VHL,PBRM1,BAP1,SETD2,KDM5C) (Figures 2B and S2D) were
binarized to +1 (positive) and 1 (negative) according to the calculated association values above and visualized in Figures 2B and
S2D using OmicsOne (Hu et al., 2019), a toolkit for data visualization and analysis of multi-omic data (https://github.com/
HuiZhangLab-JHU/OmicsOne). The cumulative density of the positive and negative associations on each individual chromosome
was counted to illustrate the propagation heterogeneity of trans associations on different chromosomal locations. For each one of
the eleven genomic events, pathway analyses were considered based on their association summary statistics with 9,190 genes
that were observed in more than 50% of the 110 clinical samples. Specifically, a quantity T = - sign(beta) log(p value) was considered
for the association between each pair of genomic event and protein abundance. The T value will be extremely high if the genomic
event is significantly upregulated in the protein abundance, extreme negative values if the genomic event is significantly downregu-
lated in the protein abundance, and values close to zero if the genomic event is not associated with the protein abundance. For each
genomic event and each pathway under consideration, we tested if T_in = T_out using a two-sided Wilcoxon rank-score test, where
T_in are the T values for all proteins inside of the pathway and T_out are the T values for all proteins outside of the pathway. Databases
from Hallmark (MsigDB Collections), KEGG, and Reactome were combined for pathway analysis (Joshi-Tope et al., 2005; Liberzon
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et al., 2011; Ogata et al., 1999). The significance threshold was set as FDR < 0.05 to identify pathways that were most significantly
associated with the genomic features. The direction of regulation (up versus down) was given by test statistics, with T_in > T_out
indicating upregulation and T_in < T_out indicating downregulation.
Correlation of mRNA and Protein Expression
A total of 7,026 genes with complete mRNA (https://cptac-data-portal.georgetown.edu/cptac/s/S050; RNA_rpkm_tumor_
normal.tsv) and protein (https://cptac-data-portal.georgetown.edu/cptac/s/S050; CPTAC3_CCRCC_Whole_abundance_gene_
protNorm = 2_CB.tsv) data across all 103 ccRCCs and 72 NAT samples were used to measure gene-wise (Figure 3A) and
sample-wise (Figures 3B and S3A) mRNA and protein correlations. Spearman correlation was calculated for each mRNA-protein
pair across tumors and NATs separately and for each individual sample across 7,026 genes (Table S4). GSEA was used for
gene-wise investigation on the correlation-ranked list of genes to determine if functional groups (pathways or complexes) were
non-randomly distributed in terms of mRNA-protein correlation (Subramanian et al., 2005). Functional classes were obtained from
the MSIGDB (https://www.broadinstitute.org/gsea/msigdb/index.jsp) and were chosen from the most significant non-redundant
functions that were biologically informative. The individual proteins associated with pathways highlighted in the text as being signif-
icantly differentially present in more- or less-correlated protein-mRNA pairs are presented. To determine which pathway or functional
activity may contribute to the sample-wise mRNA-protein correlation, we calculated the Spearman correlation between index and
protein expressions across 103 tumor samples for 7,026 proteins using the correlation as index for each sample. Similarly, functional
pathways were enriched and selected in those high correlations by GSEA enrichment analysis using the correlation-ranked list of
proteins (Figures 3B, 3C, S3B, and S3C). In addition, we assessed the association between DNA aberrations such as CNV data
and mutations and clinical phenotypes such as tumor grade. A univariate linear model was utilized in which the pairwise correlation
was modeled as a linear function of DNA aberrations and clinical phenotypes (Table S4). To assess whether the association between
pairwise correlation and those covariates was induced by their shared dependence on tumor purity, tumor purity was included in the
linear model as a covariate (Table S4). All figures were visualized using OmicsX (Pan et al., 2019), a webserver for data analysis and
visualization (http://bioinfo.wilmer.jhu.edu/OmicsX/).
Differential Abundance of mRNA, Protein, and Phosphoproteome Measurements
Principal Components Analysis
We performed PCA on 103 tumor samples and 80 normal adjacent (NAT) samples to illustrate the global proteomic difference
between tumor and NAT samples (Figure 4A). The PCA function under the scikit-learn R package (Pedregosa et al., 2011) was
implemented for unsupervised clustering analysis with the parameter ‘n_components = 20 on the expression matrix of global prote-
omic data containing 7000+ proteins (features). The 95% confidence coverage was represented by a colored ellipse for each group,
which was calculated based on the mean and covariance of points in each specific group (tumor and NAT).
Global Heatmap
Two-way hierarchical clustering was applied to the global proteomic data on samples and proteins to identify the global differential
protein expression and protein co-expression patterns (Figure S4A). Each gene expression value in the global proteomic expression
matrix was transformed to a z-score across all samples. For the sample-wise and protein-wise clustering, distance was set as
‘‘Euclidean’’ distance, and the weight method was ‘‘complete.’’ The z-score-transformed matrix was clustered using R package:
pheatmap (version 1.0.10).
Tumor versus Normal Differential Proteomic Analysis
TMT-based global proteomic data were used to perform differential proteome analysis between tumor and normal samples (Figures
4B, S4B, and S4C; Table S5). A Wilcoxon rank sum test was performed to determine differential abundance of proteins between
tumor and normal samples. The significantly differentially expressed gene lists (fold change > = 2 and FDR < 0.05) were used to
perform overrepresentation enrichment analysis (ORA) implemented in WebGestaltR (Wang et al., 2017), in which the parameters
were set to use 9190 background genes and the combined KEGG/HALLMARK/Reactome database as described above.
Accounting for Tissue Purity in Differential Analysis based on Proteomic Data
NAT and tumor tissues represent mixtures of epithelial, stromal and immune cells. TSNet (Petralia et al., 2018) was used to account
for this tumor heterogeneity and identify proteins that are differentially expressed between pure-tumor and pure-NAT cells. TSNet
models the global abundance of each protein as a mixture of pure component and a component that captures the immune and stro-
mal infiltration in a particular tissue. This algorithm estimated a mean parameter for pure component and immune/stromal infiltrated
component for each protein. TSNet was applied to tumor (T) and NAT (N) samples separately by estimating the following twomodels:
xT;i;j = pT;iyT ;i;j + ð1pT;iÞzT ;i;j
xN;i;j = pN;iyN;i;j + ð1pN;iÞzN;i;j
with yT;i;j  NormalðmYT;j; sYT;jÞ, zT ;i;j  NormalðmZT ;j; sZT ;jÞ, yN;i;j  NormalðmYN;j; sYN;jÞ, zN;i;j  NormalðmZN;j; sZN;jÞ, xt;i;j being the observed
global abundance of sample i and gene j for tissue t˛fT ;Ng, pt;i being the tissue purity for sample i and tissue t and ðyt;i;j; zt;i;jÞ being
latent variables corresponding to the protein abundance that would be observed in pure-tissue (i.e., yt;i;j) and immune/stromal cells
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(i.e., zt;i;j). Given the consistency of purity values estimated by TSNet and ESTIMATE (Yoshihara et al., 2013) for this analysis, purity
was inferred via ESTIMATE and considered as fixed (Table S7). Before implementing TSNet, each protein was z-score normalized
across NAT and tumor samples. Once that the signal was deconvolved into pure-tissue and immune/stromal components, we iden-
tified proteins that were differentially expressed in pure tumor component compared to pure NAT component. Mathematically, this
was achieved by assessing the significance of the difference between the means mYN; j and m
Y
T; j for each protein j. Significance was
assessed via permutation. Specifically, TSNet was implemented under permuted data, where the labels of NAT and tumor samples
were randomly shuffled. For this analysis, 200 permutations were considered. Using the null density of mean difference derived
based on permutated data, we assessed the significance of the up/downregulation in tumor compared to NAT. In particular, at a spe-
cific FDR cut-off of 10%, true associations were computed using the strategy illustrated by Tusher et al. (2001). To be consistent with
the differential analysis based on un-deconvolved data, among the selected proteins at FDR 10%, only mean differences with a fold
change greater than two were considered significant. Reported pathways are listed in Table S5.
Accounting for Anatomic Region of NAT
Using published gene signatures (Lindgren et al., 2017), NAT samples were allocated to different anatomic regions, including cortex,
medulla, corticomedulla (Tal), inflammatory (Infla), and endothelial and/or smoothmuscle cells or fibroblasts (SMC). Gene expression
of all the genes (TPM) was z-scored normalized across samples and then averaged across genes mapping to each anatomic region
subtype. Each sample was then allocated to the anatomic group with the highest score. A one-sidedWilcoxon test was performed to
compare ccRCC versus NAT samples allocated to the cortex anatomic region. P valueswere adjusted formultiple comparisons using
a Benjamini Hochberg adjustment. Only proteins with an adjusted p value less than 5% and fold change greater than two were
considered significant. Reported pathways are listed in Table S5.
Metabolic Reprogramming in ccRCC
A Wilcoxon rank sum test was performed to explore tumor-normal differential analysis for RNA and protein at the gene level (Fig-
ure 4C). Genes associated with glycolysis, the TCA cycle (Krebs Cycle), and oxidative phosphorylation (electron transport chain)
were focused for metabolic reprogramming. In tumor samples, metabolic reprogramming-associated genes were selected, and
z-score transformation was performed. For genes detected at both the mRNA and protein levels, t tests were performed to compare
the gene/protein expression between tumor and NAT, separately. The log2 fold changes were used to measure the expression
difference and significance and the concordance between mRNA level and protein measurements. Finally, the difference of log2
fold change between mRNA and protein were input into GSEA (Table S4) to investigate enriched pathways. The enriched concepts
indicates the discordance between mRNA and protein for tumor/normal difference (Figures 4D and S4C). Figures 4D and S4C were
visualized using OmicsX (http://bioinfo.wilmer.jhu.edu/OmicsX/) (Pan et al., 2019).
Phosphoproteomic Analysis
Phosphopeptide Analysis – Kinase and Substrate Regulation
To discover the phosphorylation events that were relevant to ccRCC, we utilized phosphopeptide-level data to examine the overall
relationship between phospho-substrates and their associated kinases (Figures 5A and S5A). The kinase-substrate association was
first extracted from PhosphoSitePlus (Hornbeck et al., 2015) to eliminate phosphopeptides (https://cptac-data-portal.georgetown.
edu/cptac/s/S050; CPTAC3_CCRCC_Phospho_abundance_phosphopeptide_protNorm = 2_CB_imputed_1211.tsv) containing
phosphosites (https://cptac-data-portal.georgetown.edu/cptac/s/S050; CPTAC3_CCRCC_Phospho_abundance_phosphosite_
protNorm = 2_CB_imputed.tsv) that were not reported as well as those without associated kinases identified in our global dataset
(https://cptac-data-portal.georgetown.edu/cptac/s/S050; CPTAC3_CCRCC_Whole_abundance_gene_protNorm = 2_CB.tsv).
Next, we inspected any substantial differences among 80 tumor/NAT pairs, especially those that showed higher changes in tumors,
by calculating the fold change (log2 scale). We then ranked each tumor (> 1.5 fold increase) among different kinase substrates to
obtain the highest ranked phospho-substrate events in the majority of tumors (Table S6). Finally, we identified nine phospho-sub-
strate events of eight kinases with inhibitors that are either FDA-approved or in clinical trials (Carles et al., 2018; Ferguson and
Gray, 2018). We also calculated the fold change of the selected phospho-substrates and kinases in other omics data (e.g.,
mRNA) to examine any difference in expression level amongmultiple omics data types (Figures S5A–S5C). In addition, we compared
the phosphopeptide expression between low-grade tumors (Grades 1 and 2) and high-grade tumors (Grades 3 and 4) as well as
between low-stage tumors (Stages 1 and 2) and high-stage tumors (Stages 3 and 4). A p value < 0.05 (Mann–Whitney U test)
was considered as significant (Figure S5B). Data were visualized using Omic-Sig (https://github.com/hzhangjhu/Omic-Sig) (Lih
et al., 2019).
Phosphoproteomic Co-expression Network Inference
Network inference was utilized to characterize co-expression patterns among phosphopeptides in ccRCC. Due to the high dimen-
sionality of phosphorylation data, which contained approximately 20,000 different peptides, phosphopeptides were first clustered
into three groups, and then co-expression networks were estimated for each group, separately (Figures 5C, 5D, and S5D–S5G). Spe-
cifically, we first summarized multiple phosphopeptides mapping to the same protein using their leading principal component, which
was derived based on 103 ccRCC tumor samples and 80 NAT samples. k-means clustering was then implemented on the gene-level
matrix to cluster proteins into three groups. This procedure resulted in one group containing 1,842 genes mapping to 6,182 phos-
phopeptides, a second group containing 1,963 genes mapping to 6,976 phosphopeptides, and a third group containing 2,047 genes
mapping to 7,818 phosphopeptides. For each group of genes, a co-expression network was estimated based on phospho-peptide
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level data through a random-forest-based algorithm (Petralia et al., 2015). In particular, co-expression networks were estimated
using missing data-imputed peptide-level phosphorylation data (https://cptac-data-portal.georgetown.edu/cptac/s/S050;
CPTAC3_CCRCC_Phospho_abundance_phosphopeptide_protNorm = 2_CB_imputed_1211.tsv). Let p represent the total number
of phosphopeptides measured for n samples. xsi;j represents the abundance of the j-th peptide mapping to the s-th protein for the i-th
sample. xsi;j wasmodeled as a function of other protein phosphopeptides, i.e., fxki;jgkss, via random forest. To facilitate the comparison
with networks inferred based on RNA-seq and global proteomic data, the network was obtained at the gene-level with nodes cor-
responding to genes. Basically, an edge between two genes was drawn if at least some peptides mapping to the two genes were
found to be associated. This was achieved by using an extension of the random forest algorithm (https://github.com/
WangLab-MSSM/ptmJRF) (Petralia et al., 2016). Basically, for each protein j, the abundance of each phosphopeptide mapping to
that protein was modeled as a function of other proteins’ phosphopeptides via random forest. At each node in the random forest
tree, M proteins were randomly sampled and proposed as candidates for the splitting rule. Then, across all phosphopeptides map-
ping to theM proteins, the phosphopeptide resulting in the lowest node impurity was utilized for the splitting rule. A separate collec-
tion of T trees was estimated for each phosphopeptide mapping to protein j. Based on each ensemble tree, an importance score
capturing the association between protein k and j was derived (Petralia et al., 2015). The final weight assigned to the relationship
ðk/jÞ was derived by taking the maximum of the importance scores across different tree ensembles. This procedure was repeated
for each protein j. The final importance score assigned to the edge ðkjÞ was derived as the average between the importance score
corresponding to ðk/jÞ and the importance score corresponding to ðj/kÞ (Petralia et al., 2016). To derive the final unweighted net-
works, a proper cut-off value was chosen via permutation techniques (Petralia et al., 2016). Specifically, 40 permutations and a FDR
cut-off of 5% were considered to derive the final network. Table S6 contains the list of network edges of genes obtained at 5% FDR
cut-off.
Phosphoproteomics Co-expression Network Modules
Network-modules were derived using Glay (Su et al., 2010), a community clustering algorithm available through Cytoscape (Morris
et al., 2011; Shannon et al., 2003). Thirty network-modules containing at least twenty genes were identified (Table S6). Considering
the list of genesmapping to each network module, pathway enrichment analysis was performed to identify biological pathways over-
represented in each network module via Fisher’s exact test. For this analysis, pathways from the KEGG (Kanehisa and Goto, 2000)
and Reactome (Joshi-Tope et al., 2005) database were considered. Table S6 shows the list of enriched pathways for each network-
module. A one-sided t test was used to identify 18 network modules whose nodes were more correlated under the Phospho-Tumor
network than under other data types (Table S6). To visualize the network modules (Figures S5D and S5E) the software iCAVE (Kalayci
and Gümüsx, 2018; Liluashvili et al., 2017) and Cytoscape were utilized.
Interactive Network Exploration Portal
Wedeveloped aweb portal that allows researchers to interactively explore tumor phosphoproteomics co-expression network and its
modules (http://ccrcc.cptac-network-view.org). This web-based application does not require users to download any software
outside of a web browser to access and explore the data. The main page features a panel on the left that enables 3D viewing and
exploration of the tumor phosphoproteomics co-expression network. Nodes are colored accordingly with associated modules
that are listed to the right of the viewing panel. Users can search for a certain gene within the network by entering the HUGO symbol
in the search box provided and clicking the Search button. If found, the gene is highlighted in the 3D panel in red, and the associated
information about the gene is provided under the search box. Gene information includes the list of genes that are directly connected
to the queried gene and also association of the gene with clinical variables (FDR value and p value for grade, gender, age, and stage).
Users can click on the name of a module to view it in detail. A separate page opens and displays module-specific network and asso-
ciated details. Module-specific pages provide the 3D network view and exploration panel at the center of the page. Users can inter-
actively explore the network in 3D using this panel. Node sizes are proportional to the number of connections. Hovering over a node
displays the gene name and highlights it in red. Clicking on a node will highlight the edges connected to the node in red and also
display associated information on the right side. Gene-associated information includes the list of genes that are directly connected
to the gene, peptides associated with the gene, and the association of the gene with clinical variables (FDR value and p value for
grade, gender, age, and stage). Above the network-view panel, another panel can perform phenotype-related search operations.
Users can select the phenotype of interest (grade, gender, age, or stage), enter an FDR cutoff value, and click the Submit button.
Genes that satisfy the search metrics are listed in the text box and are also highlighted in the network panel in red. Users can click
the Reset button to return to the original network. On the left side of the network view panel, an interactive table showing the list of
enriched pathways (if any) is provided. Users can click on a pathway name, and the genes within the pathway will be listed in the text
box aswell as highlighted in the network panel in red. Users can click the Reset button to return to the original network. The interactive
network exploration portal utilizes multiple client-side Javascript libraries (e.g., three.js, D3.js, JQuery) to facilitate visualization and
user interaction with large volumes of data in real time. For 3D visualizations that are displayed within the interface, we incorporated
3D layouts from iCAVE (Kalayci andGümüsx, 2018; Liluashvili et al., 2017) and customized them to serve the specific needs of our tool.
We also incorporated other utility libraries (e.g., dataTables.js) for data manipulation and interaction. For web interface styling, we
relied primarily relied on Bootstrap v3.3.7, integrated with our customCSS elements. Since our implementation utilizes only standard
libraries and does not necessitate any external plug-ins, the portal runs on all modern web browsers.
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ccRCC Inter-Tumor Proteome Heterogeneity
Proteomic Subtyping
We investigated the molecular subtyping of all tumor samples based mainly on global proteomic expression to identify the associ-
ations between the multi-omics expression and clinical phenotypes, such as tumor stage and grade (Figure 7B; Table S5). The 3,567
(50%) most variable global proteins without missing values were analyzed by CancerSubtypes (Xu et al., 2017) for consensus
clustering (Monti et al., 2003) of tumor subtypes. Specifically, 80% of the original sample pool was randomly subsampled without
replacement and partitioned into three major clusters using hierarchical clustering, which was repeated 500 times (Wilkerson and
Hayes, 2010). The expression values were transformed into Z scores at the gene level using the built-in standardization function
of R. The consensus-clustered samples were ordered according to the calculated distance and associated with stage and grade,
four key mutations (VHL, PBRM1, SETD2, and BAP1), and the consensus clustering results from other omics data, including immune
subtypes. Proteins were grouped into three clusters using hierarchical clustering. The overrepresentation analysis (ORA) was per-
formed on the gene list of each protein cluster using WebGestaltR (the R Version of WebGestalt). The parameters were set as
described above. The significance threshold was set as FDR < 0.05 to identify and annotate the pathways most-associated with
each protein cluster.
Multivariate Analysis
To investigate the possible associations between genome-/proteome-wide data and clinical features, we utilizedmultiple omics data
including RNA-seq, proteome, and phosphoproteome of tumor and NAT samples to conduct the association analysis (Figures 7A,
S7A, and S7B; Table S5). We also incorporated CNV and DNA methylation data from tumors only in the analysis. Our set of clinical
features consists of tumor characteristics (e.g., stage, grade, margin status, left-right kidney laterality, presence of necrosis), patient
properties (e.g., age, gender, BMI, country of origin), lifestyle, medical history (e.g., smoking, alcohol, diabetes), and sample handling
parameters (ischemic time). We also included Immune and Stromal scores computed by ESTIMATE (Yoshihara et al., 2013) as pre-
dictors because they reflect crucial TME properties (Figure 6E). In our linear regression analysis, stage, grade, age, BMI, ischemic
time, and Immune and Stromal score were used as numerical variables, whereas the remaining variables were treated as categorical.
For alcohol and smoking status, lifetime non-drinkers or non-smokers were compared to the rest of the population. For country of
origin, European countries (in this case, Poland and Ukraine) were compared to all other countries. p values obtained for each
gene in multivariate linear regression were corrected using Benjamini-Hochberg adjustment (Benjamini and Hochberg, 1995). The
values of all adjusted p values for all clinical features and all data types in both tumor and adjacent normal are provided in Table
S5. Figure S7A contains the number of genes with adjusted p value below 10%. To identify molecular pathways associated with
tumor grade, we began with the pathway gene sets obtained from KEGG, Reactome, and Hallmark databases (Joshi-Tope et al.,
2005; Kanehisa and Goto, 2000; Liberzon et al., 2011) and removed pathways that contained more than 500 genes. For proteome
andmRNAdata, we computed log10(FDR) for genes with positive associations and negative associations, where FDR is the adjusted
p value for a gene’s association with grade. On this dataset, we ran a one-sided Wilcoxon rank-sum test for each pathway gene set
versus all other genes. These p values were then corrected using Benjamini-Hochberg adjustment. A score for each pathway was
computed as (+/)log10(p-adj), depending on whether the rank-sum test p value showed it to be more up- or downregulated
compared to other genes. Table S5 lists the scores of all pathways with adjusted p value < 0.01. Figures 7A and S7B present a subset
of pathways significantly associated with grade that were selected to be representative, non-redundant, and as informative as
possible regarding the biological functions contained in the full set.
Immune-based Clustering of ccRCC tumors
Subtype identification based on cell type composition
The abundances of 64 different cell types in 175 ccRCC samples (103 tumor samples and 72 NAT samples) were computed via xCell
(Aran et al., 2017). For this analysis, FPKM (Fragments Per KilobaseMillion) mRNA expression values were utilized. Table S7 contains
the final score computed by xCell for different cell types for the 175 samples. Based on these 64 signatures, consensus clustering
was performed to identify groups of samples with the same immune/stromal characteristics. Consensus clustering was performed
using the R packages ConsensusClusterPlus (Monti et al., 2003; Wilkerson and Hayes, 2010) within the Bioconductor package Can-
cerSubtypes (Xu et al., 2017). Specifically, 80% of the original 175 samples were randomly subsampled without replacement and
partitioned into six major clusters using the Partitioning Around Medoids (PAM) algorithm, which was repeated 200 times (Wilkerson
and Hayes, 2010). Figure 6A shows the heatmap of scores for key cell types from the 175 ccRCC samples. The four tumor sample-
based subtypes were tested for association with clinical variables (e.g., tumor grade) and genomic aberrations such as chr14 loss via
a Chi-Square test of independence (Table S7). The upregulation of immune and stromal cells in a particular immune group based on
tumor samples was assessed using a multivariate linear regression in which the score of each immune and stromal cell was modeled
as a function of immune groups. First, every score was normalized across tumor samples by subtracting themean and dividing by the
standard deviation. Then, the score of the j-th cell for sample i was modeled as:
xi;j =
X4
k = 1
bk;j1ði˛ IkÞ+ εi;j (1)
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with εi;j  Nð0;sjÞ, Ikbeing the set of samples belonging to the k-th immune cluster, 1ðAÞbeing an indicator function equal to 1 if the
event A occurs and 0 otherwise, and bk;j being the coefficient capturing the association between gene j and the k-th immune group.
Benjamini-adjusted p values can be found in Table S7.
Estimation of Stromal and Immune Scores
ESTIMATE (Yoshihara et al., 2013) was also used to infer tumor purity and immune and stromal scores based on RNA-seq data and
global proteomic data (Figure S6B; Table S7). For the analysis of global proteomic data, only proteins with no missing values across
all samples were considered. As shown in Table S7, immune and stromal scores based on global proteomic data and RNA-seq data
were highly correlated (i.e., a Pearson correlation between immune scores based on RNA-seq and proteomic data higher than 0.85
and Pearson correlation of stromal scores higher than 0.75 for both NAT samples and ccRCC tumor samples). For this comparison,
only samples overlapping between the two data types were considered (i.e., 103 ccRCC tumor samples and 72 NAT samples).
Validation of microenvironment scores using DNA methylation data
Edecwas used to infer the tumor composition fromDNAmethylation data (Table S7). Edec is based on the principle that DNAmethyl-
ation measured from whole bulk tumor is the linear combination of measurements from individual cell types weighted by their cell
proportions. For the reference methylation profiles, we collected DNA methylation data (represented as beta-values) for five cell
types – kidney cancer epithelial cells, kidney normal epithelial cells, fibroblasts, endothelial cells and immune cells (Table S7). Using
a one-versus-all t test, we selected the methylation probes that distinguish the given cell type from other cell types. The probes were
then mixed for the data deconvolution.
Immunohistochemistry (IHC) validation of immune cell compositions
Formalin-fixed, paraffin-embedded 5 mm tissue sections were stained in batches for CD4, CD8, and CD163 in a central laboratory at
the Johns Hopkins Hospital according to standard automated protocols. Deparaffinization and rehydration were performed, followed
by antigen retrieval and antibody staining. CD4 and CD8 IHCwas performed using the Ventana Benchmark Ultra autostaining system
(Roche) using mouse monoclonal anti-CD8 (C8144B) antibody (Cell marque) and rabbit monoclonal anti-CD4(Sp35) antibody
(Roche), followed by detection with the iVIEW DAB Detection Kit (Roche). CD163 IHC was performed on the Leica Bond MAX autos-
taining system (Leica Biosystems) using anti-CD163 (10D6) antibody (Leica Biosystems) followed by detection with Bond Polymer
Refine Detection kit (Leica Biosystems). For tissue section imaging, slides were imaged using a Ventana iScan HT slide scanner
(Roche) and processed using the Ventana Virtuoso software (Roche) (Figure S6D).
Analysis of Differentially-Expressed Genes and Pathways
Genes that were upregulated and downregulated in each of the four immune clusters were identified based on 103 tumor samples.
For each data type, every feature vector was normalized by subtracting the mean and dividing by the standard deviation. For each
data type, the expression level of gene j and ccRCC sample i (i.e., xi;j) was modeled via Equation (1). Model [1] was implemented for
each gene j. Table S7 shows upregulated and downregulated genes identified based on different data types. Considering genes that
were up- and downregulated with Benjamini’s adjusted p value lower than 10%, a Fisher’s exact test was implemented to derive
enriched pathways (Figures 6B and S6E; Table S7) (Benjamini and Hochberg, 1995). For this analysis, pathways from the Reactome,
KEGG and Hallmark databases were considered and as background the full list of gene/proteins observed under each data type was
utilized. Pathway scores for 103 ccRCC tumor samples and 80NAT samples were computed based on combined z-score using the R
package GSVA (Hänzelmann et al., 2013). Pathway scores based on different data types can be found in Table S7. Only combined
z-scores of some key enriched pathways (Figure S6E) were included.
Angiogenesis and T-Effector Signatures
Using package GSVA (Hänzelmann et al., 2013), Angiogenesis (VEGFA, KDR, ESM1, PECAM1, ANGPTL4, and CD34) and T-Effector
(CD8A, EOMES, PRF1, IFNG, and CD274) signatures (McDermott et al., 2018) were computed for 103 ccRCC samples. Upregulation
of these signatures in a particular immune group was assessed via (1) (Figure 6F; Table S7).
Immune-based clustering on The Cancer Genome Atlas (TCGA) data
Based on 103 ccRCC samples, we selected genes that were differentially expressed in each of the four immune groups (CD8+ In-
flamed, CD8- Inflamed, VEGF Immune Desert, Metabolic Immune Desert) using the function TCGAanalyze_DEA from the package
TCGAbiolinks (Colaprico et al., 2016) and following our previously-described workflow (Silva et al., 2016). In particular, only genes
with 10% FDR cut-off and log fold change greater than 1 were selected. Following this procedure, 2,252 unique genes were selected
across different immune groups (i.e., 1,067 for CD8+ Inflamed, 721 for CD8- Inflamed, 1,054 for VEGF Immune Desert and 898 for
Metabolic Immune Desert). Based on this set of genes, the one-class regression model, OCRL (Sokolov et al., 2016) was applied to
construct a CPTAC data-based classifier for each immune group. The logistic regression model was trained using the R CRAN pack-
age, gelnet. The OCRL pipeline returned a 2,252 dimensional vector of weights for each immune group, i.e.,Wi with˛ f1; 2,3,4} Then,
TCGA kidney renal clear cell carcinoma (KIRC) samples were allocated into immune groups based on two scores that were computed
using the set of 2,252 pre-selected genes. Specifically, for the k-th sample in TCGA data and each immune group i, the following two
scores were computed:
Score 1: Spearman correlation between the model’s weight vector and the k-th TCGA sample’s expression profile, i.e., Zik =
corðWi;XkÞ with Xk being a 2,252 dimensional vector containing expression levels of the 2,252 genes for the k-th TCGA sample.
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The correlation betweenWi and Xk would be high if the k-th TCGA sample belonged to the i-th immune group. Scores fZskgwere
normalized to be in the unit interval {0,1} by subtracting the lowest value and then dividing by the maximum value.
Score 2: Spearman correlation between the k-th TCGA sample’s expression profile and the s-th CPTAC sample’s expression
profile of 2,252 genes, i.e., Ssk = corðYs;XkÞwith Ys being a 2,252 dimensional vector containing expression levels of the pre-
selected 2,252 genes for the s-th CPTAC sample, Xk being a 2,252 dimensional vector containing expression levels of the
2,252 genes for the k-th TCGA sample. This score was computed for each CPTAC sample s belonging to the i-th immune group.
Scores fSskgs˛Ii were normalized to be in the unit interval {0,1}. The final score measuring the association between the k-th TCGA
sample and the i-immune group (i.e., QikÞ was obtained by averaging scores fSskgs˛Ii with Ii being the set of samples in the i-th
immune group.
The first score (i.e., Zik ) was utilized previously to classify samples (Malta et al., 2018). In this study, a second score was considered
to avoid cases in whichmultiple immune categories resulted in the same score. In particular, the final score was derived by averaging
scores fZikg and fQikg, i.e., Xik = ðZik +QikÞ=2: Finally, to each TCGA sample k, the immune group with the highest score was as-
signed, i.e., Gk = arg maxiXik . This final score can be found in Table S7. This classification resulted in 126 samples allocated to
theCD8- Inflamed group, 156 samples allocated to theCD8+ Inflamed group, 135 samples allocated to theMetabolic ImmuneDesert
and 78 samples allocated to the VEGF ImmuneDesert group (Table S7). This TCGA-based classification was compared to that based
on CPTAC data in terms of immune and stromal cell infiltration, pathway activities and keymarkers that were found to be upregulated
in different immune groups based on CPTAC data. Similarly to CPTAC data, the concentration of different immune and stromal cells
was computed via xCell (Aran et al., 2017) (Table S7), while the activity of key pathways was derived via a combined z-score (Hän-
zelmann et al., 2013) (Figure S6E; Table S7). To identify immune and stromal cells upregulated in different immune groups, the strat-
egy adopted for CPTAC data was utilized (Model 1, Table S7).
Clinical Outcome of Immune Groups
Immune groups based on TCGA data were utilized to better understand the clinical outcome and expected survival for
different immune groups (Figures S6G and S6H). Overall survival data and tumor grade information for 495 TCGA KIRC samples,
deposited in the Genomic Data Commons (GDC) Data Portal, were downloaded using the function GDCquery_clinic from the pack-
age TCGAbiolinks (Colaprico et al., 2016). Table S7 shows Benjamini’s adjusted p values (Benjamini and Hochberg, 1995) from a
pairwise Log Rank test comparing survival curves that correspond to different immune groups. Kaplan-Meier overall survival
curves were generated using the function TCGAanalyze_survival from the package TCGAbiolinks (Colaprico et al., 2016). The
association between high-grade tumors (i.e., grade 3 and 4) and immune groups was assessed via a Chi-Square test of indepen-
dence (Table S7).
QUANTIFICATION AND STATISTICAL ANALYSIS
Transcriptomic Quantitation
The resulting BAM files were analyzed for expression using feature counts against a transcriptomic reference based on Gencode 26.
The resulting gene-level counts for protein-coding genes were transformed into FPKMs using edgeR.
Proteomic and Phosphoproteomic Quantitation
Whole proteome and phosphopeptide-enriched datasets were processed separately but using the same pipeline steps as described
in the ‘‘Protein database searching and quantification of global and phosphoproteomic data’’ section of the STARMethods. A tutorial
describing all steps of the analysis, including specific input parameter files, command-line option, and all software tools necessary to
replicate the results are available at https://github.com/Nesvilab.
The statistical details of all experiments have been reported in the manuscript text, figure legends and corresponding STAR
Methods section descriptions. Data analysis was performed in Excel, R, and Python.
DATA AND CODE AVAILABILITY
Raw data files for proteomic analysis reported in this paper are hosted by the CPTAC Data Portal and can be accessed at: https://
cptac-data-portal.georgetown.edu/cptac/s/S044 and https://cptac-data-portal.georgetown.edu/cptac/s/S050. Genomic and tran-
scriptomic data files can be accessed at: https://portal.gdc.cancer.gov/. Processed data utilized for this publication can be accessed
at: https://cptac-data-portal.georgetown.edu/cptac/s/S050.
Several custom coding softwares were generated as part of this study and have been referenced in the corresponding STAR
Methods section and listed with links to the coding script in the Key Resources Table: software codes generated by the Cieslik lab-
oratory for genomic analyses (CNVEX and CRISP), by the Nesvizhskii laboratory for proteomic data processing (Philosopher and
TMT-Integrator) by the Wang lab for data imputation (DreamAI), and by the Zhang lab for data processing and neoantigen detection
(NeoFlow and PepQuery).
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Interactive data analysis tools were generated by theWang lab: a web-based application for visualizing a heatmap of 22,867 genes
across 110 samples can be accessed at: http://ccrcc.cptac-data-view.org; a web-based application for interactively exploring
ccRCC phosphoproteomic co-expression networks (3,614 nodes, 11,200 edges) and their modules is available at: http://ccrcc.
cptac-network-view.org/.
Additional Resources
The CPTAC program website, which includes details about program initiatives, investigators, and datasets, can be accessed at:
https://proteomics.cancer.gov/programs/cptac
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Supplemental Figures
Figure S1. Impact of Genomic Alterations on Transcriptomic and Proteomic Abundances, Related to Figure 1
(A) The number of RCC and NAT samples subjected to ‘‘WGS’’ (whole genome sequencing), ‘‘WES’’ (whole exome sequencing), ‘‘DNAMethylation,’’ ‘‘RNA-seq,’’
‘‘Proteomics,’’ and ‘‘Phosphoproteomics’’ analyses. The presented numbers reflect the number of samples processed that passed data quality control (QC)
metrics. (B) Principal Component Analysis (PCA) of RNA-seq data for all CPTAC tumors (n = 110). Identified outliers are annotated by color coding (right).
(legend continued on next page)
(C) Outlier samples were further investigated for copy number variations (WGS) and somatic mutations (WES). (D) B-allele frequency plots (derived from
WES (black dots) and WGS (colored)) for two samples indicate loss of heterozygosity by uniparental disomy for chr 9 and 10 for two index samples. (E)
Frequency ofSETD2mutation distribution across tumorswithout translocation events and tumorswith t(3:2) (ch3/2), t(3:5) (ch3/5), and other (ch3/O) translocation
events. (F) SETD2 protein abundance distribution across tumors without translocation events and tumors with t(3:2) (ch3/2), t(3:5) (ch3/5), and other (ch3/O)
translocation events. (G) Co-occurrence of VHL, PBRM1, BAP1, SETD2, and KDM5C gene mutations in ccRCC tumors (n = 103). (H) Heatmap of 14 CpG probe
beta-values associated with the CpG island methylator phenotype (CIMP) profile of ccRCC tumors. CIMP status and Stage are annotated (top).
Figure S2. Impact of Copy Number Variation (CNV) on Protein Abundance, Related to Figure 2
(A) Results of iProFun associations of CNV lr (adjusted log coverage-ratios), CNV baf (B-allele frequencies), and DNA methylation. Average posterior probability
was calculated for association of genomic alteration events and mRNA, global protein, and phosphosite abundance. (B) Venn diagram of CNV (lr), CNV (baf), and
DNAmethylation genomic alterations for mRNA, protein, and phosphosite association overlap. (C) Heatmap of multi-omic data for methylation cis-cascade event
(VGLL4, PLCL2) and for DNAmethylation not detected at themRNA level (protein and phosphosite only) (IQSEC1,BCL9L,AHDC1). Tumor samples were ordered
by increasing DNA methylation z-score (left to right). (D) Associated enriched upregulated (red) and downregulated (blue) pathways of cis- and trans-effects for
five key tumor suppressor genes (VHL, PBRM1, BAP1, SETD2, and KDM5C) (adjusted p < 0.05).
Figure S3. Correlation of mRNA and Protein Abundance in ccRCC and NATs, Related to Figure 3
(A) Violin plots of tumor and NAT sample-wise correlation frequency and median distribution. (B) Sample-wise correlation of NATs ranked from high to low. NATs
were evenly distributed into three groups: high (blue), middle (gray), and low (gold). Corresponding tumor grade is indicated below. (C) Boxplots of ribosomal gene
expression (mRNA and protein), translation factor expression (mRNA and protein), and Pol I associated regulatory factors based on NAT high/low sample-wise
correlation ranking (*p < 0.05).
Figure S4. Differential Expression of Transcriptomic and Proteomic Profiles between ccRCC and NAT Protein Expression, Related to
Figure 4
(A) Heatmap of protein expression abundances between ccRCC and NAT samples. Hierarchical clustering discriminated tumors (left) from NAT (right) (n = 5745)
(B) Volcano plot of significantly differentially expressed proteins (log2 fold-change > 1; Benjamini-Hochberg adjusted p < 0.05) (n = 820; 565 downregulated, 255
upregulated). (C) Scatterplot of differential gene expression between ccRCC tumors and NATs at mRNA and protein levels using log2-fold changes. Each dot
represents one gene; x axis: protein, y axis: mRNA, respectively. Negative values indicate a decrease and positive values an increase in gene expression between
tumor and NAT. Upregulated pathways in ccRCC samples were shown.
(legend on next page)
Figure S5. Expression Changes of Phospho-Substrates in Multiple Omics Data and the Network Module of Cell Cycle, Related to Figure 5
(A) Fold change (log2 scale) of 80 tumor/NAT pairs in phospho-substrates based on mRNA and global proteome expression. (B) Comparison of phosphorylation
levels of PKM (top) and CDK1 (bottom) phosphopeptides between low grade/stage tumors and high grade/stage tumors (Mann–Whitney U test, p < 0.05). (C) Two
phospho-substrates, AKT1S1 and SMAD3 showed substantial differences in mRNA and phosphopeptide expression when comparing tumors to NATs. (D)
Phosphopeptide co-expression network module displaying ‘‘Cell Cycle’’ pathway enrichment. (E) Phosphopeptide co-expression network module displaying
‘‘Angiogenesis’’ pathway enrichment. (F) Pairwise correlation of nodes at multi-omics levels of the ‘‘Angiogenesis’’ co-expression network module. (G) Heatmap
of ‘‘Angiogenesis’’ module expression with grade, BAP1 and chromosome 14 loss, and genome instability distribution annotated.
Figure S6. Immune-Based Subtyping of ccRCC Tumors, Related to Figure 6
(A) Histologic assessment of xCell-generated cell signatures. Representative H&E stained tissue sections verifying mesangial cell, immune infiltration, and
stromal infiltration signatures. (B) Comparison between RNA-seq and global proteomics in estimating immune and stromal cell infiltration based on 103 ccRCC
tumor samples and 72 NAT samples. Correlation between scores based on RNA-seq and global proteomics data was higher than 0.75 for both tissue types.
(legend continued on next page)
Stromal and immune scores were computed via ESTIMATE. (C) Comparison of stromal and immune scores between CPTAC, TCGA, andGTEx data. Stromal and
immune scores were computed via ESTIMATE using RNA-seq data. (D) IHC profiling of immune cell populations in ccRCC. FFPE sections were stained for CD8,
CD4, andCD163 proteinmarkers to determine CD8+ T cell, CD4+ T cell, andmacrophage abundance in ccRCC tumor tissues. The scale bar indicates 200 mm. (E)
Boxplot of pathway scores for different immune groups based on RNA-seq and proteomics data from 103 CPTAC ccRCC tumor samples and 80 CPTAC NAT
samples. Pathway scores were computed via combined z-score. Pathways upregulated in CD8+ Inflamed tumors included ‘‘APM,’’ while pathways upregulated
in CD8- Inflamed tumors included ‘‘ECM’’ and ‘‘Platelet Degranulation.’’ Pathways upregulated in VEGF Immune Desert tumors included ‘‘RAP1 Signaling,’’ while
pathways upregulated in Metabolic Immune Desert tumors included ‘‘MTOR Signaling’’ and ‘‘Mitochondrial.’’ (F) Z-Score based on Angiogenesis (VEGFA, KDR,
ESM1, PECAM1,ANGPTL4,CD34) and T-Effector (CD8A, EOMES, PRF1, IFNG,CD274) signatures fromMcDermott et al. (2018). Upregulation of each signature
in a particular immune group was assessed via multivariate model (*** adjusted p < 0.001). (G) Distribution of CD8+ T cells, endothelial, and fibroblast cell
concentrations for different immune groups based on 103 CPTAC ccRCC samples and 495 TCGA KIRC samples; RNA-seq-derived cell signatures. (H) Kaplan-
Meier curves of survival data stratified by immune groups derived based on 495 TCGA KIRC samples. VEGF Immune Desert samples displayed increased
overall compared to other groups (p value = 0.0004). CD8+ Inflamed subgroup samples displayed decreased overall survival compared to all the other groups
(p value = 5e-04).
Figure S7. Proteomic Inter-Tumor Heterogeneity of ccRCC and Associated Functional Pathways, Related to Figure 7
(A) Results from multivariate analysis association of multiple ‘‘omics’’ levels. RNA-based Immune Score, RNA-based Stromal Score, and grade associated with
multiple data types (B) Cellular pathways (right) with positive (red) or negative (blue) associations (adjusted p < 0.05) at protein or mRNA level (left). Heatmap of
mRNA transcript expression associated with high and low grade tumors (center) (Benjamini-Hochberg adjusted p < 0.05).
